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Dear colleagues,  
 
We were pleased with the comments we received on our manuscript  
“A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.” 
Please find attached the revised version of our manuscript, revised according the comments and 
suggestions of the reviewers.  
We have answered all comments raised by the reviewers point by point and submitted this together with 
the modified version, and we have included both a track changes version and a final version with all 
changes implemented. 
No part of this manuscript has been published before nor is it under the consideration of another 
journal. All authors have read and approved the manuscript. No figures or tables were taken from 
another journal.  
The total word count is now 7750 words. Figures have now been uploaded as .tif files, one combination 
figure was made in order to reduce the total number of figures and tables to 6.  
We look forward to receiving the comments on this revised version.  
With kind regards, on behalf of my co-authors,  
 
Martin J van den Bent   
Cover Letter
We appreciated the thorough reviews we received, which all address important issues. Hereunder we 
reply to their comments point by point. : 
 
Reviewer #1: The authors present a review of the new WHO Classification of Tumors of the Nervous 
System from the perspective of the clinician-user. The review focuses on adult gliomas and the 
integration of molecular diagnosis and histopathological diagnosis in the final diagnosis of the several 
entities. The review is a critical review with the opinion of the authors on different issues; therefore, one 
may disagree with the authors' opinions.  Nevertheless, the review provides insights and perspectives on 
several aspects of tumor classification and guidelines for the readership. 
The WHO has a mission to propose guidelines universally that, due to the differences in technological 
advances and resources between countries, socialized versus insurance-based medical systems, 
academic and private medical practices, may lead to disparities in implementation of these guidelines. 
Despite these caveats, the 2016 WHO classification of brain tumors provides a modern integrated 
classification with several diagnostic tools that can be used by the great majority of pathologists either 
in their own practices or in tertiary referrals centers. 
As the authors have emphasized, any tumor classification is a moving target since new data may appear 
at the moment of its compilation. The WHO series of classification of tumors are assembled on 
evidence-based data and common-sense of their users. This sometimes takes time. Therefore, it is not 
surprising that while some users are still trying to understand the new proposals and changes of the 
2016 classification, others are already proposing new modifications like the authors. 
As commented before, one may have different opinions than those presented by the authors, and this 
reviewer has several of them. But these are not a point for review; they are differences of opinions. 
However, one point should be addressed by the authors. The 5 examples illustrated by the authors with 
neuroimaging and the results of the molecular diagnosis are a proof that neuro-oncology has to be 
practiced in a multidisciplinary manner from the review of the clinical presentation, the interpretation of 
imaging, neurosurgical approach, and integrated histopathological and molecular diagnosis. The way the 
authors choose to illustrate the cases minimize the value of histopathological diagnosis as the initial step 
for the pathological diagnosis and a guide for molecular diagnostics. Also, it minimizes the need for 
multidisciplinary tumor board review for each individual patient in a systematic manner.  
A: We thank the reviewer for the summary, and of course if anything, the used MR images emphasize the 
need for multidisciplinary boards: they shows the value of re-examining the MR images when more 
diagnostic information is received, be it pathological or molecular. We have now emphasized that more 
clearly in the manuscript. We could have added microscopy to the images, but since clinicians are more 
involved in the review of MR images we choose not to.  
 
 
Response to Reviewers
Reviewer #2: The abstract reads a little clumsy. E.g. " Recent data have shown that analysis of genetic 
lesions allow a better prognostic and predictive classification of diffuse glioma." NOt sure this is the 
main point to start with; it's about diagnostic accuracy, not prediction or prognosis. 
A: This is indeed the heart of the matter, and a key element where the discussion on how to classify 
tumors is about. But, diagnostic accuracy is not all there is, a diagnosis can be accurate but not 
informative if it does not inform about outcome. The current classification is also one that is better suited 
for therapeutic recommendations, but we agree this is not about true prediction and more about 
treatment selection. The text has thus been modified accordingly, with some additional changes to meet 
the word limit.  
 
There is some claim to focus on adults, but the authors then continue with the lesion from pediatric 
GBM and also include medulloblastoma. It should be consistent. The speculative part (chromosome 7 
gain and 10 loss patients to be considered as molecular GBM), IDH mut GBM to be renamed and the 
desire for a rapid transition from new findings into a classification is not harboring the same level of 
evidence as the prior statements and exceeds WHO CNS 4+; therefore I would leave the abstract for the 
facts from the WHO interpretation and put this less solid part into the main text. From this reviewer's 
perspective there would be enough to tell about the clinical implications of the classification and no 
need for "political statements in the abstract". Along the same lines, the classification process should be 
stringent and this does not allow to jump on every new finding. 
A: In view of the comments we received we have deleted the section on medulloblastoma, which was 
indeed (and deliberately) superficial. The 7+/10q loss data are currently considered strong enough to be 
taken into consideration for treatment decisions by the many clinicians that have access to this type of 
diagnostics.  In fact, this notion is also present in the Blue Book texts on low grade astrocytoma ( page 
26),  AOA (page 76)and AOD (page 74). This is an area where the knowledge has been accumulating, for 
which reason we write in the manuscript: “then the WHO classification could consider going beyond the 
IDHwt diagnoses”. It is also left as a consideration in the abstract, but to meet the comment we have 
rephrased the first ‘should’ into ‘could. Indeed,  when it comes to individual patients we cannot wait 
when deciding on treatment.  With respect to the political statements, this has really been an issue.  
In the main text 'The Genotype trumps the histological phenotype': 
 
The statement "The demonstration that a molecular correlate of oligoastrocytoma does not exist, 
consistent with large differences in outcome of anaplastic oligoastrocytoma" is not quite correct and not 
quite reflecting the cited references. The main message is molecular separation and dependent on the 
pathologist. It is not gone, because there are differences in interstudy comparisons. It might be useful to 
check another early reference on that topic (Wiestler et al. ANP 2014, ATRX loss refines the classification 
of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis ). 
A: ATRX mostly helps identifying the IDHmt but 1p/19q intact anaplastic glioma. The quoted manuscript 
is on the NOA4 study on anaplastic glioma. Interestingly, the same authors made clear  in another 
manuscript on NOA4 (Wiestler et al, Integrated DNA methylation and CNA, Acta Neuropathologica) 
2014) that 24 of investigated 115 NOA4 tumors were CIMP negative and molecularly resembling 
glioblastoma. The paper quoted by the reviewer primarily identifies with ATRX staining the IDHmt  
1p/19q intact tumors, and thus the better prognosis of these tumors compared to the glioblastoma like 
cases (and the slightly less favorable outcome compared to co-deleted cases).  Since ATRX mutations are 
not present in all IDHmut 1p/19q non-codeleted tumors and has at present not been associated with 
outcome within the subgroup of these IDH mutated 1p/19q intact tumors, we do not think this reference 
add to this review. Of note, these manuscripts are also supporting the identification of 7+/10q LOH 
tumors because of their poor outcome. We were already quoting this reference, we now also quote it in 
the section on 7+/10q LOH tumors 
Consider medulloblastoma. It is now presented as a major focus, but discussed only very superficial. 
A: We only entered the remark on medulloblastoma to acknowledge the molecular change that occurred 
here, without the intent of going into details; obviously the focus is on adult glioma. It was not intended 
as a major focus, and also in view of the comments of the other reviewers we have deleted it. 
Further below a confusing statement is "One solution would have been to add to the 2016 classification 
the categories of (anaplastic) oligodendroglioma, IDHwt, as a way out of difficult to diagnose cases that 
undoubtedly will surface. The use of NOS for childhood oligodendroglioma without 1p/19q loss and IDH 
mutations is confusing, as in adults NOS restricted to those cases where testing was not possible or was 
non-conclusive." Although this reviewer tries to understand, what the authors want to say, it may need 
some context for the general reader. 
A: We have tried to clarify  this sentence to make it better understandable. 
The "political" statements on the turn of cycles for the WHO classification is not accurately reflecting the 
present situation and would be better placed at the end. I have difficulties to understand, why the 
authors criticize the cycles although these are given by the WHO process, plus efforts exist to find more 
rapid updates, in which at least some of the autors are involved. A separate classification for sure would 
not solve the issue.  
A: This is indeed an issue, we do understand the existence of a WHO process, but we do not agree with 
the fact that that process in itself governs the timing of revisions, and not the emerging data.  This is 
simply not  a patient centered approach, and this is perceived by many as an area of friction. 
The genes suggested for testing should be prioritized as some are integral part of the classification and 
some are interesting (and relevant like MGMT), but some like EGFR or BRAF and others are nothing but 
a trial target at this given moment, which alone should not place it into the context of a clinical WHO 
commentary. 
A: indeed, many of these these genes are not present in the WHO classification but based on recurrent 
questions we felt the discussion of genes that are proposed for testing in daily clinics was relevant for 
this review.  
One caveat is regarding the integration of imaging. It should be stated, in which cases and what fore this 
is necessary. Sampling error (which is less of an issue)... 
A: We fully agree with this point. In general, this should be done in all cases: MRI images should always 
be consistent with the diagnosis, if not this should induce suspicion and more scrutiny. This is now more 
clearly stated in the manuscript.  
 
Reviewer #3: This is a review of the new WHO classification for CNS tumors.  This is a topic that warrants 
discussion among clinical neuro-oncologists as it has the potential to dramatically change the 
therapeutic approach to several entities (eg. IDHWT low grade gliomas).  However, this review reads as 
a criticism of the new classification and makes recommendations about adding or subtracting molecular 
testing depending upon the circumstances.   This is potentially very dangerous, given that this new 
scheme is only a few months old, few people are completely facile with all the nuances of this new 
approach and that additional testing may or may not be available to everyone - a major reason the 
current update was limited to examine IDH and 1p19q status.  Thus, the focus/purpose of the review is 
murky and not well organized which dramatically limits its usefulness to the reader. 
A: we understand the concern of the reviewer, but it is no secret this revision has been subject to a 
debate and this debate is not resolved; moreover new developments will raise new issues. I have full 
confidence in the critical minds of the readership of Neurooncology, and in our view this journal should 
not avoid such discussion. 
1.  On page 4 the authors state that the use of NOS is not recommended if IDH testing was inconclusive 
or unavailable. Really?  They don't propose an alternative. There will always be times when testing is 
inconclusive - for a variety of reasons - so what is the option in view of the fact that knowledge of IDH 
status is co side red parse punt to treatment planning?  At least NOS makes clear that the pathologist 
attempted (or thought o) the testing but results were not available.  This seems reasonable to me, and 
was suggested after enormous consideration by the most experienced tumor neuropathologists in the 
world.   
A: To our defense, we took this ‘not recommended’ for NOS from an presentation given by one of the 
leading participants to the WHO 2016 revision. When checking the text, we indeed found no similar 
remark, neither in the blue book nor in the 2016 review by Louis.  We have therefore deleted this 
sentence.  
2. The discussion on page 5 in Disappearing Glioma Entities presumes access to the WHO 2016 text.  The 
diagnosis of gliomatosis cerebri was always based on the imaging which is something a clinician would 
always consider when deciding upon treatment.  This reader is not sure how suggesting that the term be 
retained by clinicians is helpful. 
A: Indeed, gliomatosis has always been a radiological diagnosis,  and clinicians continue to consider the 
spread of tumor when deciding on radiotherapy. It has therapeutic consequences, but it remains ill 
defined. We fully agree though that it is no longer part of the WHO classification. 
3.  On the one hand, the authors recommend completely different nomenclature for GMB, IDH mutant, 
suggesting they are called astrocytoma grade IV IDH mutant.  They make the point about prognosis but 
there have been many know factors which affect GBM survival (such as age), but we didn't call the 
tumor by a different name in different age groups to reflect that difference.  On the other hand, at the 
end of the paper they actually suggest that IDH testing be limited to patients aged 15-55!  This is in 
direct contradiction with the new criteria and their argument on page 6-7 that IDH should be at the 
"heart" of the astrocytoma diagnosis.  This seems enormously confusing and counterproductive to make 
these suggestions.   
A: The reviewer touches upon critical points.  With respect to the remark on age and other prognostic 
factors, the WHO classification considers tumor morphology, and now includes molecular factors. They 
do not and never did consider clinical factors, and rightly so. What we propose is based on molecular 
factors, and part of the classification. We therefore do not see the argument clinical factors, which are 
clearly outside the testing of the tumor sample.  
With respect to the proposed age limit for IDH: we did not propose to limit testing to the age of 15-55 
years, we wrote “Testing for IDH is part of routine diagnostics, but it seems reasonable to limit routine 
testing to an age range of 15 to 55 years, for example, and test beyond that only on clinical indications 
(e.g. in all adult grade II and III glioma, and in case of a hemispheric astrocytoma in a 13 year old).”; 
acknowledging that testing beyond is useful on indication. So basically  the question is what the 
diagnostic yield will be to test for IDH mutations in case of a tumor in a 63 year old patient with the 
histological diagnosis of a glioblastoma and an MR lesion consistent with a glioblastoma.  As with other 
diagnostic tests, some considerations about diagnostic yield makes sense as opposed to simply testing 
without further considerations. We have made the proposal for  the upper age range for routine testing 
testing somewhat broader as there are no data to support a strict cut off.   
 
4. The figure legends for the pictures of figures 3 and 4 are reversed and it's not clear in the text where 
they want which picture.   
A: we apologize, while editing the text we failed to update the figure legends, this is now corrected (on 
top, two of the images have been combined).  
5. The brief sections on medulloblastoma, ependymoma and the "WHO cycle" seemed to be dropped 
into the middle of this paper.  The authors then cycle back to the gliomas. This is confusing and seems 
disorganized. All the glioma information should be together.  One could argue that the other tumors 
could even be eliminated from this discussion. 
A: as mentioned above, we intended only to touch upon medulloblastoma,  and we have this section now 
removed. We bought some more background information on the status of molecular testing of 
ependymoma, which is after all a subgroup of the glioma.  
6. On page 9, one could argue that clinicians have long ago adopted some aspects of molecular 
classification, especially 1p19q loss.  I think that this version of WHO is actually catching up to the clinical 
approach to these patients - not the other way around. 
A: We fully agree, and would deplore the situation in which the clinically used classification would 
become distant from the official WHO classification.   
7. Given the current state of glioma therapeutics, it is unclear what the additional testing for TERT and 
chromosome 7+/10q- adds, given that many clinicians already view lower grade gliomas that are IDH WT 
as having a poor prognosis and moving to treat these patients. At this time, the additional information 
of further poor prognostic features would t change the treatment decision.  This doesn't mean that 
further testing isn't appropriate within clinical trials or research environments, but to call for routine use 
of these features seems a bit over the top (pages 12-13).  
A: This in fact becomes more and more part of the clinical approach to these patients, we do not think 
this is really over the top. We have rephrased the sentence in the abstract with recommendations for 
testing, indeed suggesting that this should be done routinely would be a bridge too far. 
8. The language needs a lot of work. There are numerous spelling and grammatical errors (fossa 
posterior).  First line, page 9 has the wrong reference (23); I don't know if other references are wrong.  
Page 17, third line from bottom saying that the FISH is "positive" is confusing here when trying to 
describe the pitfalls of partial deletion.  There is a lot of redundancy which is also confusing and the 
authors do contradict themselves in multiple places - some of which I've listed above, but most 
importantly they recommend additional testing in most places and not even the basic testing in many 
others. 
A: Ref 23 is on the use of methylation arrays to distinguish between poor prognosis and good prognosis 
fossa posterior ependymoma, with similar histological appearance. This reference is checked and correct. 
Of note, this part of the text has been revised and ref nr have been changed.  We have rephrased 
‘positive’ by ‘loss’ to avoid misunderstanding. The text was prepared with several native speakers, if 
errors still exist the corresponding author is to be held accountable for that. We do not agree we 
recommend ‘not even the basic testing in many others’,  as mentioned above  we try to be cost efficient 
in the use of resources and refrain from testing in cases where any patient benefit is quite unlikely.  
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Abstract 
The 2007 WHO classification of brain tumors  did not use molecular abnormalities as diagnostic criteria. 
Studies Recent data have shown that analysis of genoetyping ic lesions allow a better prognostic and 
predictive classification of diffuse glioma with improved treatment selection. This has resulted in a major 
revision  of the WHO classification, (‘WHO 2016’) which  is now for the adult diffuse glioma centered 
around IDH and 1p/19q diagnostics. This revised classification is reviewed with a focus on adult brain 
tumors, and includesing a recommendation of genes of which routine testing is clinically useful. Apart 
from  assessment of IDH mutational status incl sequencing of R132H-immunohistochemistry -negative 
cases and testing for 1p/19q several other markers can be considered for deserve routine testing, 
including assessment of copy number alterations of chromosome 7 and 10, and of TERT promoter,  BRAF 
and H3F3A mutations. For ‘glioblastoma, IDH mutated’  the term astrocytoma grade IV cshould be 
considered. It should be considered to treat IDH-wild type grade II and III diffuse glioma with polysomy of 
chromosome 7 and loss of 10q as glioblastoma.  New developments must be more quickly translated 
into further revised diagnostic categories. Quality control, and rapid integration of molecular findings 
into the final diagnosis and the communication of the final diagnosis to clinicians require systematic 
attention. 
 
Keywords: WHO classification, glioma, IDH, 1p/19q codeletion, 7+/10LOH 
  
[Geef tekst op] [Geef tekst op] N-O-D-16-00602R1 
3 
 
Formatted: Dutch (Netherlands)
‘The Genotype trumps the histological phenotype’1 
The World Health Organization (WHO) classification of Tumors of the Central nervous System is the 
standard and universally used diagnostic system for the classification of brain tumors. It was originally 
built on the morphological appearance of tumor cells and their resemblance to normal brain cells, with a 
grading system based on the outcome of tumors if left untreated. In recent years however classical 
histopathology with a limited incorporation of genetic changes was no longer meeting current clinical 
needs, as illustrated by  
- The notorious interobserver variation in the classification and grading of in particular of grade II 
and III gliomas2 
- The demonstration that a molecular correlate of oligoastrocytoma does not exist, consistent 
with large differences in outcome of anaplastic oligoastrocytoma 3-5 
- Molecular reclassification of gliomas containing more prognostic information compared to 
classical histopathology6-9 
- Different molecular subclasses of medulloblastoma associated with a different age at 
presentation and with different outcome10 
The common denominator in all these observations is the additional information contained in the 
molecular profile of histologically similar tumors allowing a more accurate classification and better 
prediction of clinical outcome compared to that according to histology alone. This insight is now 
reflected in the conceptual change of the 2016 revision of the ‘WHO Tumours of the Nervous System’ 
(table 1).1011  In an evidence-based manner, key molecular markers such as mutations in isocitrate 
dehydrogenase (IDH) gene and 1p/19q status are now central in the description of brain tumors. For 
clinicians, this revision is timely and reflects the beginning of an era in which molecular diagnostics are 
integral to the diagnostic classification.  This present review focusses on the major changes the WHO 
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
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2016 brings to the glioma classification of the central nervous system tumors (table 1), and discusses 
which genetic alterations are useful for routine assessment and their implementation in the clinic. 1112  
The WHO 2016 classification: from IDH to Not Otherwise Specified (NOS) 
For practicing neuro-oncologists, the changes in the classification of the diffuse gliomas are the most 
relevant as these are by far the most frequent adult primary brain tumors.  The above quote ‘genotype 
trumps phenotype’ is limited to the context of glioma diagnostics and is based on the assessment of IDH 
mutations and 1p/19q status in diffuse glioma. A tumor with oligodendroglial morphology, showing an 
IDH mutation but no 1p/19q loss will be designated astrocytoma, IDH mutated, whereas tumor with 
features of a glioblastoma but IDH mutated and 1p/19q co-deleted will be designated an anaplastic 
oligodendroglioma (figure 1a).  For diffuse (anaplastic) astrocytoma and glioblastoma without IDH 
mutations, the term IDH wild type is used (e.g., astrocytoma IDH wild type).  If molecular testing for IDH 
status could not be completed or was inconclusive the term ‘Not Otherwise Specified’ (NOS) is used (e.g., 
resulting in ‘glioblastoma ‘IDH wild type’, glioblastoma ‘IDH-mutant’, and glioblastoma NOS).  This use of 
NOS is however not recommended. Except for childhood oligodendroglioma, the diagnosis (anaplastic) 
oligodendroglioma requires demonstration of both an IDH mutation and combined 1p/19q loss:  the 
current WHO classification does not consider (anaplastic) oligodendroglioma without IDH mutation and 
1p/19q co-deletion a distinct tumor entity. That leaves cases with in which the local pathologist finds an 
(anaplastic) oligodendroglial morphology but in which neither 1p/19q loss nor an IDH mutation is 
detectable an orphan category, of unknown frequency and clinical significance. The WHO 2016 
classification recommends in that situation to consider other diagnoses, and in particular of glioblastoma 
in case of combined presence of polysomy of chromosome 7 and loss of 10 (see below) but that indeed 
typical genetic aberration is still not considered diagnostic (see below). One solution would have been to 
add to the 2016 classification the categories of (anaplastic) oligodendroglioma, IDHwt, as a way out of 
Field Code Changed
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difficult to diagnose cases that undoubtedly will surface.  The use of NOS for childhood 
oligodendroglioma without 1p/19q loss and IDH mutations is confusing, as in adults the use of this term 
‘NOS’ is restricted to those cases where testing was not possible or was non-conclusive. Future updates 
of the WHO classification may consider how these disparate clinico-pathologic entities may be classified 
more precisely. Two other mutations have become diagnostic classifiers:  ‘RELA fusion positive 
ependymoma’, and ‘diffuse midline glioma, H3 K27M mutant’. Despite these changes, in general 
genotyping alone should not be used for glioma diagnostics: alterations must be understood in the 
context of the findings of a diffuse glial tumor. Nonetheless, in rare cases histopathology may fail to find 
evidence of tumor, but genetic analysis may reveal typical alterations allowing a classifying diagnosis 
(figure 2). 
 
Disappearing glioma entities 
With this emphasis on 1p/19q and IDH, mixed oligoastrocytoma do not exist in the molecular WHO 2016 
classification and what is left are morphological oligoastrocytoma in which the molecular testing was not 
completed or inconclusive (NOS).  Studies have made clear that mixed oligoastrocytoma are usually 
either IDH mutated, 1p/19q co-deleted, or IDH mutated but 1p/19q intact; at the molecular level truly 
mixed tumors do not exist (the rare anecdotal reports do not really contradict that).3, 123, 13 Hence, similar 
to the classification of oligodendroglioma, it is inconsistent that we have anaplastic astrocytoma IDH wild 
type, but no (anaplastic) oligoastrocytoma IDHwt as this can potentially be one of the diagnoses 
rendered (although the text states that in these in anaplastic mixed cases a glioblastoma should be 
considered no molecular criteria for this have been defined , see below). Another entity that disappeared 
from the classification is “gliomatosis cerebri”. The prior diagnosis of gliomatosis cerebri was based on 
the radiological appearance of a diffuse tumor involving more than one lobe without histological 
Field Code Changed
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specifications. It has long been recognized that this definition was very subjective, with outcome and 
sensitivity to treatment again reflecting the molecular background.13, 1414, 15 In the current classification, 
widely infiltrating glioma  are now designated according to their molecular profile. Whether widely 
infiltrative phenotypes have specific clinical correlations compared to more localized tumors requires 
further study.  For clinicians, its use may continue to be helpful for some cases as initial radiotherapy 
may be less attractive. At present this radiological diagnosis is however quite loosely defined. 
 
Grading: IDH mutant astrocytoma grade IV vs glioblastoma? 
The revised WHO 2016 does not address grading at the molecular level. There are several reasons for 
this.  First, in IDH mutated histologically grade II and III tumors the impact of histological grade on 
survival may be less compared to the impact of grade in tumors of unknown IDH mutational status .1516 
Clearly though, histopathological characteristics do have an impact on outcome on IDH mutated tumors 
as well, as grade IV IDH mutated glioblastoma tend to have a worse outcome compared to grade II and III 
tumors. A re-analysis of The Cancer Genome Atlas (TCGA) confirmed the relevance of grade in all 
molecular subtypes of diffuse glioma.1617   At present, there are however insufficient data on molecular 
abnormalities within molecularly defined subgroups that allow a robust and reproducible 
prognostication. Although some lesions indicative of poor prognosis have been identified (e.g., LOH 9p in 
1p/19q co-deleted tumors, PI3 kinase mutations in IDH mutated 1p/19q intact tumors), they need 
validation in larger and independent series .16-1817-19  But it appears a missed opportunity that the naming 
of ‘glioblastoma, IDH mutant’ has not been further addressed. In the WHO 2016 these tumors continue 
to be lumped with the variants of glioblastoma, but these tumors are different from a metabolic 
perspective, occur in younger patients and have a better outcome compared to IDHwt glioblastoma. To 
be consistent, a consideration would have been to label these tumors astrocytoma grade IV IDH mutant 
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in order to distinguish them from IDHwt glioblastoma. That would also have put the IDH mutation at the 
heart of the ‘astrocytoma’ diagnosis, similar to the role of the 1p/19q co-deletion in oligodendroglioma. 
It would reflect the molecular similarities of these tumors, and the gradual and subjective differences 
between grade II, III and IV IDH mutated astrocytic tumors.  
The genetic identification of glioblastoma in histological grade II and III lesions 
The absence of IDH mutations confers a worse prognosis in diffuse grade II and III glioma, but much 
more can be said about these tumors. Indeed, some IDHwt diffuse astrocytoma or the 
oligoastrocytoma/oligodendroglioma present without histological features of glioblastoma (necrosis, 
endothelial proliferation) have genetic lesions typical of glioblastoma: gain of chromosome 7, loss of 10q 
and TERT promoter (TERTp) mutations. 6, 8, 196, 8, 20 Usually these patients are 50 years or older, and they 
typically have a poor outcome. Some of these cases may be explained by sampling error obtained of ring 
enhancing lesions with a necrotic center, but others are observed in sometimes large tumors without 
any enhancement on MR scanning. Although the WHO classification mentions that in 1p/19q intact 
anaplastic oligodendroglioma and in anaplastic oligoastrocytoma with gain of 7 and loss of 10 a 
glioblastoma must be considered, these tumors continue to be diagnosed as astrocytoma, IDH-wild type 
or oligodendroglioma/oligoastrocytoma (figure 1b3).  The same holds true for entities in which only 
TERTpmutations are found without an IDH mutations and which usually have a clinical course similar to 
glioblastoma.2021 If it is accepted that “genotype trumps phenotype”, then the WHO classification could 
consider going beyond the IDHwt diagnoses, and make a next classifying step in grade II and III tumors 
with glioblastoma-like molecular characteristics. Clinicians are already becoming inclined to treat these 
tumors like glioblastoma, indeed one approach could be to call them ‘grade III glioblastoma’.  Signature 
GBM molecular alterations should be codified to define these tumors, as clearly  other subsets of IDHwt 
Field Code Changed
Field Code Changed
[Geef tekst op] [Geef tekst op] N-O-D-16-00602R1 
8 
 
Formatted: Dutch (Netherlands)
LGG’s do not have the molecular characteristics of GBM and instead represent other entities on a 
biologic level.   
Medulloblastoma 
The other group with major changes are the medulloblastomas.  Four different molecular subtypes of 
medulloblastoma are defined: Wingless-type MMTV integration site family member (Wnt) activated, 
sonic  hedgehog (SHH)-activated and TP53 mutant, SHH activated and TP53-wild type and 
medulloblastoma non-Wnt/non-SHH comprising both group 3 and group 4 medulloblastoma. This 
classification reflects the revolutionary insights in the molecular classification of medulloblastoma into 
four subtypes, obtained in large scale collaborations.10 For medulloblastoma, the fallback position for no 
molecular diagnostics is the classical histopathological definition (classical, desmoplastic/nodular, 
extensive nodularity and large cell/anaplastic). The chapter on this entity makes some ambiguity clear: 
both a classification based on molecular biology and on classical pathology are offered.  
Ependymoma 
New studies on large multicenter datasets on ependymoma have yielded an enormous amount of new 
biological knowledge.21, 22{Pajtler, 2015 2582 /id; These have resulted in proposal for an ependymoma 
classification in 9 subgroups, or 6 if subependymoma are left out. At the molecular level ependymoma 
subgroups exists, In supratentorial ependymoma fusion genes involving and a RELA  (occurring in up to 
88% of childhood supratentorial ependymoma) and YAP1 (10%) have been identified fusion protein has 
been identified which occurs in up to 70% of childhood supratentorial ependymoma which are absent 
but not in fossa posterior ependymoma. 2122 The RELA fusion ependymoma are now part of the WHO 
2016 classification, but not the YAP1 fusion ependymoma. Using methylation arraysIn in fossa posterior 
ependymoma, two completely different subtypes of fossa posterior ependymoma subtypes can be 
distinguished: genome wide methylation arrays are able to distinguish between EPN-PFA (high risk for 
Formatted: Do not check spelling or grammar, Superscript
Field Code Changed
[Geef tekst op] [Geef tekst op] N-O-D-16-00602R1 
9 
 
Formatted: Dutch (Netherlands)
progression, median age at diagnosis 3 years but occurring in 11% of adults),  and low risk tumors (good 
prognosis, EPN-PFB, occurring in 45% of ependymoma patients between 10 and 17% and in most 
patients over 18 years). Importantly, classification using methylation arrays has more prognostic and 
diagnostics significance compared to classical histopathology. In fact, the currently available data suggest 
that analysis with methylation arrays a in a clinically relevant distinction between tumors that post-
operatively need further RT because of poor prognosis (EPN-PFA) and favorable prognosis tumors (EPN-
PFB) that after extensive resection allow a conservative approach; whereas histopathology does not 
allow this distinction. 2223   This is another area where clinical knowledge already deviate from the WHO 
2016 diagnostic classification, and with therapeutic implications. , which potentially could be used for 
clinical decision making on post-operative radiotherapy. 23 That is however not part of the current 
classification, and This example  further emphasizes the need to continue the refining of molecular 
diagnostics and its incorporation into the WHO classification, and the need to consider non-mutational 
diagnostics (here: epigenetics) as clinically relevant classifiers. 
The 7-year cycle of WHO: beyond the realm of pathology 
Indeed, the WHO classification of brain tumors is a moving target: as time goes by, novel molecular 
entities will be defined (and with the observations on 7+/LOH10q tumors, at the time of the WHO 2016 
publication the field has moved already).2223 The mission of the WHO “blue book” series is to provide a 
description of neoplastic entities that balances the need for a universally applicable system of 
classification, while at the same time allows for changes that are warranted based on the evidence from 
current research. In so doing it acknowledges that while appropriate molecular markers can be critical to 
classify tumors appropriately, they are not always universally available and in such cases, allowance must 
be made to ensure and promote, to the extent possible, an accurate classification that can be widely 
applied. That automatically implies though that this diagnostic standard may not reflect the advance of 
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medical care. As long as these new developments have only limited clinical correlates (either in terms of 
prognosis or treatment options) this will be not be a major issue, but once these findings have clinical 
implications that perception will rapidly change and friction arises with the clinicians using the diagnostic 
system for day to day treatment decisions. Another consequence of the rapid genetic developments is 
that revisions are required more frequently. To that end, the recent iteration of the WHO classification 
was termed an “update”, in accordance with the queue in the WHO blue book series.   It is estimated 
that in several years the time will be appropriate for the formal revision, but facts occurring ‘on the 
ground’ may dictate otherwise and require earlier revisions. In addition, it is axiomatic that this 
diagnostic classification requires more diverse multidisciplinary input, including molecular biologists, 
clinicians and radiologists, who represent the “end-users” of the classification. A ‘worst case scenario’ is 
an  ‘exit’  variant in the field of neuro-oncology: clinicians defining their own classification.   
 
Which genes should be routinely assessed? 
For glial tumors, the emphasis in the WHO 2016 classification is on IDH and 1p/19q. More frequently 
mutated genes have however been identified in glioma, like CIC, FUBP and ATRX, many of which appear 
to be subclonal.6, 23-266, 24-27 Others are clearly clonal, like TERTp and TP53. They currently serve no role in 
the WHO 2016 classification but they may have some significance though, especially if more advance 
diagnostics platforms are used that routinely assess a wider spectrum of abnormalities. Incorporating 
these in routine diagnostics may help to better understand the overall picture, and increase the overall 
reliability of a molecular diagnosis even if they are not essential for any diagnosis. In contrast, other rarer 
mutations in BRAF and histone genes (H3F3A, HIST1H3B) indeed identify tumors with specific clinical 
characteristics. Of these, H3F3A K27M mutations have been included in the new WHO classification, with 
the designation of a new entity, the ‘diffuse midline glioma, H3 K27M mutant’. This raises the question 
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as to which should be routinely assessed, which are optional but nice to have and which are without 
clinical relevance.  
1p/19q co-deletion.  
This is now part of standard diagnostics. 1p/19q loss was first identified in 1994 as the most 
characteristic genetic lesion in oligodendroglioma, associated with chemotherapy response in 1998, and 
subsequently assumed to be both prognostic for survival and predictive for benefit from the addition of 
PCV chemotherapy to radiotherapy.27-3028-31 This combined 1p/19q loss is the result of a still poorly 
understood balanced translocation, in which both the whole p-arm of chromosome 1 and the whole q 
arm of chromosome are lost (‘classical’ 1p/19q co-deletion).31, 3232, 33 More recent data suggest that 
typical 1p/19q loss is always associated with IDH mutations.6, 7, 26, 336, 7, 27, 34 Since 1p and 19q loss 
occasionally occurs in other tumors, the finding of a 1p/19q deletion in the absence of an IDH mutation 
does not allow the diagnosis of an oligodendroglioma (figure 34). In childhood tumors with 
histopathological appearance of an oligodendroglioma 1p/19q  loss is usually absent, but 1p/19q co-
deletion is occasionally identified in newly diagnosed oligodendroglial tumors in patients beyond 65 
years of age.3435  
 
IDH mutations 
Assessing IDH mutations is now also part of standard diagnostics. Two types of IDH mutations are 
observed in glioma: in the IDH1 and in the IDH2 gene.  All mutations in IDH1 and IDH2 are somatic, 
missense, heterozygous, and affect codon 132 (IDH1) or codon 172 (IDH2). IDH mutations are mutually 
exclusive; 90% of all IDH mutations concern the IDH1 R132H mutation. Studies have shown that IDH 
mutations are early events in gliomagenesis, and remain present at the time of tumor progression.35, 3636, 
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37  IDH mutated tumors occur in all grade II-IV diffuse glioma, but are absent in other primary brain 
tumors. If found in other histological subtypes this is likely to represent a histopathological 
misclassification. IDH mutations are common in adult grade II and III glioma, occurring in 70-80% of 
cases.36, 3737, 38 About 5-10% of glioblastoma show IDH mutations, in particular in patients below 50 years 
of age. In pediatric glioma IDH mutations are rare, but have been described in patients as young as 12 
years of age.3839 IDH mutated tumors have an improved outcome compared to non-IDH mutated tumors 
of similar histopathological grade. IDH mutations cause an altered enzyme substrate affinity, leading to 
increased levels of 2-hydroxyglutarate and lower levels of α-ketoglutarate.3940  One of the metabolic 
alterations that this induces is the development of a global methylation of CpG islands, including the 
MGMT gene promoter. This may explain some of the chemotherapy sensitivity of IDH mutated tumors; 
another explanation is that some of the chemotherapy resistance mechanisms are depending on α-
ketoglutarate.4041 It has been suggested IDH mutations can be used to identify patients that will benefit 
from adding chemotherapy to radiotherapy, other studies were however not confirming this and 
identified MGMT promoter methylation as the best predictive factor which is however usually present in 
IDHmt tumors.41, 4242, 43   
TP53 
TP53 mutations are predominantly observed exon 4-8, and occur in 95% of IDH mutated tumors without 
1p/19q co-deletion. They do however also occur in other glial tumors, including glioblastoma, in 1p/19q 
co-deleted tumors (although less frequently), in medulloblastoma and in pediatric glioma. Therefore 
they lack diagnostic specificity and in glial tumors they are not associated with treatment outcome.  
There is currently no role for routine testing; if diagnosed they may support the diagnosis of several 
entities. 
Alpha-thalassemia syndrome gene (ATRX) 
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Mutations in the ATRX gene occur in 70% of IDH mutated gliomas without 1p/19q co-deletion, the 
astrocytic type of glial tumor. They are mutually exclusive with TERT promoter (TERTp) mutations. There 
are no hot spot regions for ATRX mutations, and they can be sub-clonal with different ATRX mutations in 
different parts of the tumor and with different ATRX mutations at first diagnosis vs recurrent tumors. If 
present, they suggest an IDH mutated TP53 mutated astrocytoma. ATRX mutations also occur in H3 
mutated tumors. ATRX mutations can be assessed by immunohistochemistry and by sequencing. Loss of 
ATRX IHC staining in mutated tumors can be a rapid method to detect ATRX mutations, and it has been 
suggested it may obviate the need for 1p/19 testing.9 While some neuropathologists use ATRX IHC as a 
criterion to select which gliomas are to be tested for 1p/19q status, further experience is needed to test 
whether it can substitute for a 1p/19q test, but for now, the WHO 2016 classification explicitly does not 
accept positive staining for ATRX in IDH mutated tumors as an alternative to diagnose 1p/19q codeleted 
IDH mutated oligodendroglioma.  
 
Telomerase Reverse Transcriptase promoter ((TERTp) mutations 
Somatic hot spot mutations in the TERTp gene occur in IDHwt glioblastoma and in 1p/19q co-deleted IDH 
mutated oligodendroglioma.  As a consequence, simply assessing both TERTp and IDH mutational status 
already results in a very powerful prognostic glioma classification.7, 20, 437, 21, 44 In some tumors only TERTp 
mutations are found, without other typical glioma alterations; these patients tend to have a poor 
outcome. TERTp mutations are mutually exclusive with ATRX mutations. Interestingly, patients with 
grade II and III IDHwt tumors but without a TERTp mutations appear to have a better prognosis 
compared to patients with TERTp mutations.  Typically, these studies have been lacking the assessment 
of chromosome 7 and 10q, which most likely would have identified a glioblastoma like chromosomal loss 
pattern in many of the IDHwt/TERTp mutated tumors.  More clinical outcome data on these tumors are 
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urgently needed. Assessment of TERTp mutational status can be useful for IDHwt diffuse glioma, they are 
however not specific for glioma and for example occur also in medulloblastoma. 
The gain of 7 and loss of 10q genotype 
The combination of tri/polysomy of chromosome 7 and LOH of 10q is a characteristic combination found 
in many glioblastoma and probably represents an early event in these tumors.19, 4420, 45  Usually TERTp 
mutations are present, and in 40-50% of cases EGFR amplification usually with EGFR mutations, including 
EGFRvIII mutations in 20%.  Many IDHwt astrocytoma and anaplastic astrocytoma (especially in patients 
over 45 years of age) show this 7+/10q- pattern, and typically have a clinically aggressive course (figure 
1b3).6, 456 Testing for this combination in patients over 45-50 years of age with grade II of III IDHwt 
tumors may give positive indications for a poor prognosis. The WHO classification strongly suggests the 
diagnosis glioblastoma should be considered in 7+/10q- anaplastic  oligodendroglioma and anaplastic 
oligoastrocytoma, but these abnormalities do not  qualify for the diagnosis glioblastoma ion the current 
classification. The available clinical data support that despite these being histologically grade II or III 
tumors, that  these tumors should be treated as glioblastoma and many clinicians with routine access to 
diagnostics of 7 and 10q do so. 
Epidermal Growth Factor Receptor (EGFR) amplification and mutations 
EGFR amplification occurs in 40-50% of all glioblastoma, and is usually associated with EGFR mutations 
and trisomy/polysomy of chromosome 7.46 Most EGFR amplified tumors also show EGFR mutations 
affecting the extracellular domain of the receptor, the most frequent being the EGFRvIII mutation. There 
is currently no drug that specifically or effectively exploits any of these mutations, although several trails 
on novel agents are ongoing. As a consequence, from both a therapeutic and a diagnostic aspect the 
routine assessing of EGFR amplification or EGFR mutations is currently not useful. The presence of EGFR 
amplification is indeed highly specific: if found it is diagnostic at the molecular level of a glioblastoma, 
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but it lacks sensitivity: assays for EGFR amplification will be negative in 50% of the glioblastoma cases. 
Outcome of EGFR amplified or EGFRvIII mutated tumors is not different from other glioblastoma.47 
Currently, for glioblastoma diagnostics assessing both chromosome 7 and 10q or TERTp mutations is 
more informative than assessing EGFR amplification status.  
Phosphatase and Tensin Homolog (PTEN) 
PTEN mutations occur in 20-30% of glioblastoma, and are as a rule accompanied by LOH10q. When both 
are present this results in bi-allelic PTEN inactivation. They may also occur at low frequency in other 
gliomas with unclear clinical significance, and in other tumors (medulloblastoma). Thus, it has low 
diagnostic value and no therapeutic consequences. Routine assessment of PTEN mutations is clinically 
not indicated.  
BRAF-KIAA fusion genes and BRAF mutations in glial tumors 
Abnormalities in the BRAF gene  are characteristic of several  subgroup of gliomas. Pilocytic astrocytoma 
(PA) in the fossa posterior typically have a tandem duplication at 7q34 resulting in a transforming fusion 
gene between KIAA1549 and BRAF (BRAF duplication or BRAF-KIAA1549 fusion gene), but not the 
BRAFv600 mutation. BRAF-KIAA fusion genes are also frequent in non-NF1 optic nerve glioma (73%).48 
BRAF-KIAA1549 fusion are age specific, they are rare in PA patients over 40 years of age (7%).  BRAFv600 
mutations are mutually exclusive with the BRAF-KIAA549 fusion gene, these are observed in , 33% of the 
non-posterior fossa PA. They are also relatively common in  pleomorphic xantroastrocytoma (PXA;  43-
66%), anaplastic PXA (65%) and ganglioglioma (18-43%) especially if located in the brain stem49-52; they 
are  rare in adult glioma (glioblastoma: 2%, adult low grade glioma: 0-3%).49  They are also frequent in 
the proposed novel (but rare) WHO entity of epitheloid glioblastoma, although their distinction from 
anaplastic PXA is unclear.53 A study on pediatric diencephalic low grade glioma reported frequent 
BRAFv600 mutated non-PA in this region, with imaging characteristics of vivid enhancement and 
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multiloculated or multinodular appearance and/or infiltrative growth on T2 weighted images (figure 2).54  
A Canadian series observed BRAF fusion positivity in unilateral thalamic low grade tumors.55 Since BRAF 
mutated tumors may be treated with targeted agents aiming at the BRAFv600 mutations, either alone or 
in combination with a MERK pathway inhibitor, the finding of this abnormality may have therapeutic 
implications. Responses to these agents have been described, and this appears a very promising avenue 
of research.56 BRAF mutations and the BRAF-KIAA fusion have not been incorporated into the current 
diagnostic classification; the diagnosis of pilocytic astrocytoma remains a morphological definition. 
Routine testing must be considered in relevant cases.  Future research should focus on establishing to 
what extent these tumors share the same background, and to what extent other abnormalities in the 
RAS/RAF pathway may have a similar phenotypic effect. More rare genetic lesions in pilocytic 
astrocytoma include NF1,  KRAS and RAS mutations and FGFR1 and other BRAF fusions.57 
Histone H3F3A and HIST1H3B mutations 
The WHO 2016 has accepted the ’diffuse midline glioma, H3 K27M mutant’ as diagnostic entity, 
occurring predominantly in childhood and adolescent brain tumor patients. The mutation is part of a 
larger family of histone mutations with similar clinical presentation. Pediatric and young adult glioma 
frequently show mutations in genes encoding H3 variants, which through histone modification alter gene 
expression.58 Driver mutations occur in the H3F3A gene (positions K27 and G34) encoding histone H3.3 
genes, and in HIST1H3B histone H3.1 gene (K27 position). K27 mutated tumors typically arise in the 
brainstem and midline structures such as thalamus and cerebellum, mostly in children and young adults. 
Thus, diffuse intrinsic pontine glioma (DIPG) frequently harbor K27M mutations in histone H3.3 genes as 
well as in H3.1 genes.59 Childhood and young adult supratentorial glioma may show mutations in histone 
H3.3, with K27M mutations occurring in midline tumors. In contrast, pG34R/V histone H3.3 mutations 
are restricted to pediatric and young adult HGGs of the cerebral cortex, and are almost invariably 
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associated with ATRX and TP53 mutations.59, 60 K27 mutations are associated with a poor outcome; G34 
mutations appear to have better survival. Intrinsic pontine glioma harboring a K27M mutation in H3.3 
are less responsive to radiotherapy, with earlier relapses and more metastatic recurrences than those in 
H3.1.60 Although the K27M mutation was frequently observed in adult brainstem and thalamic gliomas, 
this mutation tended to be associated with a poorer prognosis in brainstem gliomas but not in thalamic 
gliomas.61  The presence of the H3F3A K27M mutation is associated with mutations in TP53.59, 62 An 
antibody against the K27M allele  may prove useful to facilitates detection of this mutation.63   The role 
of other mutations (e.g., ACVR1) in DIPG remain to be elucidated. Testing for H3F3A mutations is 
insightful in pediatric and young adult cases with midline tumors. 
 
Challenges: platforms and tests to be used 
The revised WHO 2016 criteria do not make recommendations how to assess molecular alterations, 
which is wise in view of the rapidly changing landscape of molecular diagnostics and testing platforms. 
With next generation sequencing techniques (NGS) becoming rapidly more affordable, NGS panels 
tailored for glioma diagnostics are increasingly being used for routine diagnostics including assessment 
of copy number alterations.64  Although there is clearly an advantage of the assessment of more than 
only IDH mutation and 1p/19q status, the routine use of screening for the 50 most frequent cancer 
genes or whole exome in glioma is without clinically proven benefit. Outside the identification of 
molecular glioblastoma with WHO grade II or III histology, no proven therapeutic decisions can be taken 
based on these profiles, with BRAF mutant tumors as the most promising exception as they allow 
patients to be selected for clinical trials.56  Previous studies have shown the clinical usefulness of gene 
expression analysis and genome wide methylation analysis. In particular, the latter approach has been 
shown to be very informative, allowing the classification of tumors without knowledge of specific 
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mutations. This classification system is based on the assumption that the methylation pattern of a tumor 
is the consequence of both the lineage of the cell the tumor arises from, and tumor specific DNA 
characteristics. For brain tumors, a relevant aspect here is that the analysis of methylation status 
simultaneously allows the assessment of MGMT status, which may well be the single most powerful 
determinant of benefit from alkylating agent chemotherapy.42, 4543, 65  
Assessment of molecular characteristics in every day practice and pitfalls 
Testing for IDH is part of routine diagnostics, but it seems reasonable to limit routine testing to an age 
range of 15 to 55 - 60 years, for example, and test beyond that only on clinical indications (e.g. in all 
adult grade II and III glioma, in the presence of oligodendroglial features, and in case of a hemispheric 
astrocytoma in a 13 year old). For the R132H mutation a very reliable immunohistochemistry (IHC) assay 
is available, but this represents only 90% of all IDH mutations.  As a consequence, IHC has at best a 90% 
sensitivity, implying that in case of IHC negativity this must be followed by sequencing for both IDH1 and 
IDH2 mutations (figure 45). IHC can be used as a first screen, but not as a tool to rule out IDH mutations. 
Testing for 1p/19q status and IDH mutations should be performed  in all patients presenting with 
possible oligodendroglial tumors. Testing for 1p/9q status should use an assay that allows assessment of 
loss of the entire 1p and 19q arm. Fluorescence in situ hybridization (FISH) for 1p using a probe for 
1p36.6 region is less specific as it may suggest loss be positive in tumors with partial 1p deletion only, 
limited to the tip of chromosome 1p.65, 6666, 67 This part can be lost without loss of the rest of 
chromosome 1p, which in combination with 19q loss has been observed in glioblastoma. If copy number 
alterations (CNA) are considered to be relevant this should be assessed with other techniques. Both 
1p/19q co-deletions and IDH mutations are early events in gliomagenesis, and  their presence or absence 
are unlikely to change over time.67, 6868, 69 Therefore, retesting of 1p/19q and IDH status at the time of a 
re-resection in tumors with already known status is of limited use, unless a significant clinical change 
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occurred indicating a second tumor.  Incorporation of assessment of TERTp mutations into routine 
diagnostics of gliomas has been suggested.2021 In the absence of 1p/19q loss,  diffuse gliomas with TERTp 
mutations tend to have a poor outcome reminiscent of glioblastoma.7, 437, 44 Although some studies on 
targeted mutation assessment have shown that in some tumors only TERTp mutations were observed, 
this deserves further clinical study since in most of these series tumors were not tested for CNA of 7 and 
10q.  
Reporting 
Centers must develop automated workflows that incorporate molecular testing in their routine 
procedures, including the incorporation of the molecular diagnostics in the final pathology result. It is 
important for the reporting of the diagnosis to be standardized and made available for capture in the 
national cancer registry databases, so the incidence of the specific entities based on molecular features 
can be reported. Since the turnaround time for histopathology is shorter than for molecular diagnostics, 
ensuring accurate and timely feedback on molecular findings in patients in whom a histopathological 
diagnosis has already been established is important. It is recommended to routinely include (MR) 
imaging characteristics in the final diagnostic considerations: MRI images should be consistent with the 
pathological diagnosis and if not this should give rise to additional scrutiny.  The interpretation of 
molecular findings depends on the context: if the tumor is unlikely to be a diffuse glioma the molecular 
findings may not contribute except when an diagnostic mutation is found with supportive MR and clinical 
findings. 
Clinical studies 
With the new classification, the clinical data from past trials without molecular analysis have become 
outdated. Since the first results of the trials on anaplastic oligodendroglioma, follow-up trials in the 
newly diagnosed setting (CODEL, CATNON) but also in recurrent disease (TAVAREC) enrolled patients 
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based on their 1p/19q status because of the difference in prognosis, and many prospective trials 
reported retrospectively on the molecular status (table 3).  New studies should now distinguish between 
IDH mutant tumors, IDH mutant and 1p/19q co-deleted, and IDH wild type diffuse gliomas. This 
complicates matters. As an example, the presence of IDH mutations also identifies a more favorable 
subgroup of glioblastoma which may also hold true at the time of recurrence.6970 This questions whether 
these tumors should be enrolled in trials on recurrent glioblastomas and whether it should be routinely 
tested for. On the other hand, the still modest survival of IDH mutated glioblastoma also argues against 
enrolling these tumors in trials aiming at IDH mutated diffuse grade II and III glioma although the limited 
difference in outcome between grade II and III IDH mutated tumors provides a rational for combining 
these grades.1516 Today’s changes emphasize that all trials should collect tissue samples as part of the 
study design. Analysis of existing datasets may help to improve our understanding of the outcome of 
these subsets of patients.  
Quality control 
In the first discussions on the incorporation of the molecular findings in the diagnosis of gliomas a 
multilayer diagnostic approach was proposed.71 This concept has been abandoned in the final WHO 2016  
revision, which unifies the diagnosis with the molecular diagnostics as the essential part of glioma 
classification. Some have proposed that the addition of the histopathological diagnosis may still be useful 
as it may contribute to the granularity of the diagnosis. The interobserver variation in the 
histopathological classification of glioma is well known,  but early experiences with inter-laboratory tests 
on diagnostic molecular assays on the same set of tumors revealed that differences between 
laboratories may exist as well.70, 7172, 73 Proper quality control is critical now that diagnostics and clinical 
decisions are based on molecular testing. Laboratories need to certify and validate their testing 
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procedures with appropriate controls. This is not exciting work and requires significant efforts, but is 
absolutely essential for reliable diagnostics.  
 
Conclusion. 
The new WHO 2016 classification for brain tumors brings molecular diagnostics to the center of glioma 
and medulloblastoma classification. This revised classification will improve treatment selection of brain 
tumor patients and clinical trial design. This will not be the last revision of this classification as new 
molecular insights into brain tumors will further refine the classification of brain tumors. Further 
refinements already seem indicated, e.g., in the IDH wild type categories of grade II and III glioma as 
these represent in many cases –especially in patients over 50 years of age- glioblastoma -like lesions with 
7+/10q LOH. Further analysis of TERTp mutational status in non-glioblastoma 1p/19q intact tumors will 
be needed to better understand the prognostic role of that mutation in diffuse glioma. More 
responsiveness to the rapidly changing and multidisciplinary field of neuro-oncology will be crucial to 
maintain a well-accepted WHO classification of brain tumors.  For this, a more transparent and 
multidisciplinary process of change of these pivotal criteria will be needed. 
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Figures 
Figure 1 Glioblastoma diagnostics anno 2016. 1a. T1 weighted MR images of a 40 year old male with a 
short history headache and difficulty walking . At histopathology a glioblastoma was diagnosed, targeted 
sequencing showed b an IDH2 mutation, combined 1p/19q loss and deletion of chromosome 9 
consistent with the diagnosis of an anaplastic oligodendroglioma; 1b. T1 weighted contrast enhanced 
MR image of a 50 year old female who developed over months progressive memory and behavioral 
complaints.  No contrast enhancement was present, at biopsy histopathology showed a grade II  
astrocytoma, Next Generation Sequencing failed to show an IDH mutation but instead documented gain 
of chromosome 7, loss of 10q, and mutations in the  EGFR  and PTEN gene consistent with a 
glioblastoma..  
Figure 2. T2 weighted images of a 25 year old male who underwent two biopsies for a mesencephalic 
lesion, on both occasions histopathological examination failed to show clear evidence of tumor. On 
mutational analysis, a BRAF mutation was found (c.1795_1797dupACA;p.T599dup) 
Figure 3. T1 contrast enhanced MR images of a ring right frontal enhancing lesion tumor 
histopathologically classified as glioblastoma,  at molecular examination 1p/19q co-deletion was found 
but with neither an IDH nor a TERTp mutation,  
Figure 4. T1 weighted contrast enhanced MR image of a 50 year old female who developed over months 
progressive memory and behavioral complaints.  No contrast enhancement was present, at biopsy 
histopathology showed a grade II  astrocytoma, Next Generation Sequencing failed to show an IDH 
mutation but instead documented gain of chromosome 7, loss of 10q, and mutations in the  EGFR  and 
PTEN gene consistent with a glioblastoma. 
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Figure 3. T1 contrast enhanced MR images of a ring right frontal enhancing lesion tumor 
histopathologically classified as glioblastoma,  at molecular examination 1p/19q co-deletion was found 
but with neither an IDH nor a TERTp mutation, 
Figure 54. T2 weighted MR images of a rRight frontal low grade astrocytoma in a 20 year old, diagnosed 
as IDH wt because of negative immunohistochemistry. After referral to a tertiary care center sequencing 
demonstrated an IDH  c.394C>T; p.R132C  mutation in combination with a TP53 and an ATRX mutation. 
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Abstract 
The 2007 WHO classification of brain tumors  did not use molecular abnormalities as diagnostic criteria. 
Studies have shown that genotyping allow a better prognostic classification of diffuse glioma with 
improved treatment selection. This has resulted in a major revision  of the WHO classification, which  is 
now for adult diffuse glioma centered around IDH and 1p/19q diagnostics. This revised classification is 
reviewed with a focus on adult brain tumors, and includes a recommendation of genes of which routine 
testing is clinically useful. Apart from  assessment of IDH mutational status incl sequencing of R132H-
immunohistochemistry negative cases and testing for 1p/19q several other markers can be considered 
for routine testing, including assessment of copy number alterations of chromosome 7 and 10, and of 
TERT promoter,  BRAF and H3F3A mutations. For ‘glioblastoma, IDH mutated’  the term astrocytoma 
grade IV could be considered. It should be considered to treat IDH-wild type grade II and III diffuse 
glioma with polysomy of chromosome 7 and loss of 10q as glioblastoma.  New developments must be 
more quickly translated into further revised diagnostic categories. Quality control, and rapid integration 
of molecular findings into the final diagnosis and the communication of the final diagnosis to clinicians 
require systematic attention. 
 
Keywords: WHO classification, glioma, IDH, 1p/19q codeletion, 7+/10LOH 
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‘The Genotype trumps the histological phenotype’1 
The World Health Organization (WHO) classification of Tumors of the Central nervous System is the 
standard and universally used diagnostic system for the classification of brain tumors. It was originally 
built on the morphological appearance of tumor cells and their resemblance to normal brain cells, with a 
grading system based on the outcome of tumors if left untreated. In recent years however classical 
histopathology with a limited incorporation of genetic changes was no longer meeting current clinical 
needs, as illustrated by  
- The notorious interobserver variation in the classification and grading of in particular of grade II 
and III gliomas2 
- The demonstration that a molecular correlate of oligoastrocytoma does not exist, consistent 
with large differences in outcome of anaplastic oligoastrocytoma 3-5 
- Molecular reclassification of gliomas containing more prognostic information compared to 
classical histopathology6-9 
The common denominator in all these observations is the additional information contained in the 
molecular profile of histologically similar tumors allowing a more accurate classification and better 
prediction of clinical outcome compared to that according to histology alone. This insight is now 
reflected in the conceptual change of the 2016 revision of the ‘WHO Tumours of the Nervous System’ 
(table 1).10  In an evidence-based manner, key molecular markers such as mutations in isocitrate 
dehydrogenase (IDH) gene and 1p/19q status are now central in the description of brain tumors. For 
clinicians, this revision is timely and reflects the beginning of an era in which molecular diagnostics are 
integral to the diagnostic classification.  This present review focusses on the major changes the WHO 
2016 brings to the glioma classification of the central nervous system tumors (table 1), and discusses 
which genetic alterations are useful for routine assessment and their implementation in the clinic. 11  
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The WHO 2016 classification: from IDH to Not Otherwise Specified (NOS) 
For practicing neuro-oncologists, the changes in the classification of the diffuse gliomas are the most 
relevant as these are by far the most frequent adult primary brain tumors.  The above quote ‘genotype 
trumps phenotype’ is limited to the context of glioma diagnostics and is based on the assessment of IDH 
mutations and 1p/19q status in diffuse glioma. A tumor with oligodendroglial morphology, showing an 
IDH mutation but no 1p/19q loss will be designated astrocytoma, IDH mutated, whereas tumor with 
features of a glioblastoma but IDH mutated and 1p/19q co-deleted will be designated an anaplastic 
oligodendroglioma (figure 1a).  For diffuse (anaplastic) astrocytoma and glioblastoma without IDH 
mutations, the term IDH wild type is used (e.g., astrocytoma IDH wild type).  If molecular testing for IDH 
status could not be completed or was inconclusive the term ‘Not Otherwise Specified’ (NOS) is used (e.g., 
resulting in ‘glioblastoma ‘IDH wild type’, glioblastoma ‘IDH-mutant’, and glioblastoma NOS).  . Except for 
childhood oligodendroglioma, the diagnosis (anaplastic) oligodendroglioma requires demonstration of 
both an IDH mutation and combined 1p/19q loss:  the current WHO classification does not consider 
(anaplastic) oligodendroglioma without IDH mutation and 1p/19q co-deletion a distinct tumor entity. 
That leaves cases with in which the local pathologist finds an (anaplastic) oligodendroglial morphology 
but in which neither 1p/19q loss nor an IDH mutation is detectable an orphan category, of unknown 
frequency and clinical significance. The WHO 2016 classification recommends in that situation to 
consider other diagnoses, and in particular of glioblastoma in case of combined presence of polysomy of 
chromosome 7 and loss of 10 (see below) but that indeed typical genetic aberration is still not 
considered diagnostic (see below). One solution would have been to add to the 2016 classification the 
categories of (anaplastic) oligodendroglioma, IDHwt, as a way out of difficult to diagnose cases that 
undoubtedly will surface.  The use of NOS for childhood oligodendroglioma without 1p/19q loss and IDH 
mutations is confusing, as in adults the use of this term ‘NOS’ is restricted to those cases where testing 
was not possible or was non-conclusive. Future updates of the WHO classification may consider how 
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these disparate clinico-pathologic entities may be classified more precisely. Two other mutations have 
become diagnostic classifiers:  ‘RELA fusion positive ependymoma’, and ‘diffuse midline glioma, H3 K27M 
mutant’. Despite these changes, in general genotyping alone should not be used for glioma diagnostics: 
alterations must be understood in the context of the findings of a diffuse glial tumor. Nonetheless, in 
rare cases histopathology may fail to find evidence of tumor, but genetic analysis may reveal typical 
alterations allowing a classifying diagnosis (figure 2). 
 
Disappearing glioma entities 
With this emphasis on 1p/19q and IDH, mixed oligoastrocytoma do not exist in the molecular WHO 2016 
classification and what is left are morphological oligoastrocytoma in which the molecular testing was not 
completed or inconclusive (NOS).  Studies have made clear that mixed oligoastrocytoma are usually 
either IDH mutated, 1p/19q co-deleted, or IDH mutated but 1p/19q intact; at the molecular level truly 
mixed tumors do not exist (the rare anecdotal reports do not really contradict that).3, 12 Hence, similar to 
the classification of oligodendroglioma, it is inconsistent that we have anaplastic astrocytoma IDH wild 
type, but no (anaplastic) oligoastrocytoma IDHwt as this can potentially be one of the diagnoses 
rendered (although the text states that in these in anaplastic mixed cases a glioblastoma should be 
considered no molecular criteria for this have been defined , see below). Another entity that disappeared 
from the classification is “gliomatosis cerebri”. The prior diagnosis of gliomatosis cerebri was based on 
the radiological appearance of a diffuse tumor involving more than one lobe without histological 
specifications. It has long been recognized that this definition was very subjective, with outcome and 
sensitivity to treatment again reflecting the molecular background.13, 14 In the current classification, 
widely infiltrating glioma  are now designated according to their molecular profile. Whether widely 
infiltrative phenotypes have specific clinical correlations compared to more localized tumors requires 
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further study.  For clinicians, its use may continue to be helpful for some cases as initial radiotherapy 
may be less attractive. At present this radiological diagnosis is however quite loosely defined. 
 
Grading: IDH mutant astrocytoma grade IV vs glioblastoma? 
The revised WHO 2016 does not address grading at the molecular level. There are several reasons for 
this.  First, in IDH mutated histologically grade II and III tumors the impact of histological grade on 
survival may be less compared to the impact of grade in tumors of unknown IDH mutational status .15 
Clearly though, histopathological characteristics do have an impact on outcome on IDH mutated tumors 
as well, as grade IV IDH mutated glioblastoma tend to have a worse outcome compared to grade II and III 
tumors. A re-analysis of The Cancer Genome Atlas (TCGA) confirmed the relevance of grade in all 
molecular subtypes of diffuse glioma.16   At present, there are however insufficient data on molecular 
abnormalities within molecularly defined subgroups that allow a robust and reproducible 
prognostication. Although some lesions indicative of poor prognosis have been identified (e.g., LOH 9p in 
1p/19q co-deleted tumors, PI3 kinase mutations in IDH mutated 1p/19q intact tumors), they need 
validation in larger and independent series .16-18  But it appears a missed opportunity that the naming of 
‘glioblastoma, IDH mutant’ has not been further addressed. In the WHO 2016 these tumors continue to 
be lumped with the variants of glioblastoma, but these tumors are different from a metabolic 
perspective, occur in younger patients and have a better outcome compared to IDHwt glioblastoma. To 
be consistent, a consideration would have been to label these tumors astrocytoma grade IV IDH mutant 
in order to distinguish them from IDHwt glioblastoma. That would also have put the IDH mutation at the 
heart of the ‘astrocytoma’ diagnosis, similar to the role of the 1p/19q co-deletion in oligodendroglioma. 
It would reflect the molecular similarities of these tumors, and the gradual and subjective differences 
between grade II, III and IV IDH mutated astrocytic tumors.  
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The genetic identification of glioblastoma in histological grade II and III lesions 
The absence of IDH mutations confers a worse prognosis in diffuse grade II and III glioma, but much 
more can be said about these tumors. Indeed, some IDHwt diffuse astrocytoma or the 
oligoastrocytoma/oligodendroglioma present without histological features of glioblastoma (necrosis, 
endothelial proliferation) have genetic lesions typical of glioblastoma: gain of chromosome 7, loss of 10q 
and TERT promoter (TERTp) mutations. 6, 8, 19 Usually these patients are 50 years or older, and they 
typically have a poor outcome. Some of these cases may be explained by sampling error obtained of ring 
enhancing lesions with a necrotic center, but others are observed in sometimes large tumors without 
any enhancement on MR scanning. Although the WHO classification mentions that in 1p/19q intact 
anaplastic oligodendroglioma and in anaplastic oligoastrocytoma with gain of 7 and loss of 10 a 
glioblastoma must be considered, these tumors continue to be diagnosed as astrocytoma, IDH-wild type 
or oligodendroglioma/oligoastrocytoma (figure 1b).  The same holds true for entities in which only TERTp 
mutations are found without an IDH mutations and which usually have a clinical course similar to 
glioblastoma.20 If it is accepted that “genotype trumps phenotype”, then the WHO classification could 
consider going beyond the IDHwt diagnoses, and make a next classifying step in grade II and III tumors 
with glioblastoma-like molecular characteristics. Clinicians are already becoming inclined to treat these 
tumors like glioblastoma, indeed one approach could be to call them ‘grade III glioblastoma’.  Signature 
GBM molecular alterations should be codified to define these tumors, as clearly  other subsets of IDHwt 
LGG’s do not have the molecular characteristics of GBM and instead represent other entities on a 
biologic level.   
  
Ependymoma 
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New studies on large multicenter datasets on ependymoma have yielded an enormous amount of new 
biological knowledge.21, 22 These have resulted in proposal for an ependymoma classification in 9 
subgroups, or 6 if subependymoma are left out. In supratentorial ependymoma fusion genes involving 
RELA  (occurring in up to 88% of childhood supratentorial ependymoma) and YAP1 (10%) have been 
identified which are absent in fossa posterior ependymoma. 21 The RELA fusion ependymoma are now 
part of the WHO 2016 classification, but not the YAP1 fusion ependymoma. Using methylation arrays in 
fossa posterior ependymoma, two completely different subtypes of fossa posterior ependymoma 
subtypes can be distinguished: EPN-PFA (high risk for progression, median age at diagnosis 3 years but 
occurring in 11% of adults), and low risk tumors (good prognosis, EPN-PFB, occurring in 45% of 
ependymoma patients between 10 and 17% and in most patients over 18 years). Importantly, 
classification using methylation arrays has more prognostic and diagnostics significance compared to 
classical histopathology. In fact, the currently available data suggest that analysis with methylation arrays 
a in a clinically relevant distinction between tumors that post-operatively need further RT because of 
poor prognosis (EPN-PFA) and favorable prognosis tumors (EPN-PFB) that after extensive resection allow 
a conservative approach; whereas histopathology does not allow this distinction. 22   This is another area 
where clinical knowledge already deviate from the WHO 2016 diagnostic classification, and with 
therapeutic implications. , This example  further emphasizes the need to continue the refining of 
molecular diagnostics and its incorporation into the WHO classification, and the need to consider non-
mutational diagnostics (here: epigenetics) as clinically relevant classifiers. 
The 7-year cycle of WHO: beyond the realm of pathology 
Indeed, the WHO classification of brain tumors is a moving target: as time goes by, novel molecular 
entities will be defined (and with the observations on 7+/LOH10q tumors, at the time of the WHO 2016 
publication the field has moved already).22 The mission of the WHO “blue book” series is to provide a 
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description of neoplastic entities that balances the need for a universally applicable system of 
classification, while at the same time allows for changes that are warranted based on the evidence from 
current research. In so doing it acknowledges that while appropriate molecular markers can be critical to 
classify tumors appropriately, they are not always universally available and in such cases, allowance must 
be made to ensure and promote, to the extent possible, an accurate classification that can be widely 
applied. That automatically implies though that this diagnostic standard may not reflect the advance of 
medical care. As long as these new developments have only limited clinical correlates (either in terms of 
prognosis or treatment options) this will be not be a major issue, but once these findings have clinical 
implications that perception will rapidly change and friction arises with the clinicians using the diagnostic 
system for day to day treatment decisions. Another consequence of the rapid genetic developments is 
that revisions are required more frequently. To that end, the recent iteration of the WHO classification 
was termed an “update”, in accordance with the queue in the WHO blue book series.   It is estimated 
that in several years the time will be appropriate for the formal revision, but facts occurring ‘on the 
ground’ may dictate otherwise and require earlier revisions. In addition, it is axiomatic that this 
diagnostic classification requires more diverse multidisciplinary input, including molecular biologists, 
clinicians and radiologists, who represent the “end-users” of the classification. A ‘worst case scenario’ is 
an  ‘exit’  variant in the field of neuro-oncology: clinicians defining their own classification.   
 
Which genes should be routinely assessed? 
For glial tumors, the emphasis in the WHO 2016 classification is on IDH and 1p/19q. More frequently 
mutated genes have however been identified in glioma, like CIC, FUBP and ATRX, many of which appear 
to be subclonal.6, 23-26 Others are clearly clonal, like TERTp and TP53. They currently serve no role in the 
WHO 2016 classification but they may have some significance though, especially if more advance 
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diagnostics platforms are used that routinely assess a wider spectrum of abnormalities. Incorporating 
these in routine diagnostics may help to better understand the overall picture, and increase the overall 
reliability of a molecular diagnosis even if they are not essential for any diagnosis. In contrast, other rarer 
mutations in BRAF and histone genes (H3F3A, HIST1H3B) indeed identify tumors with specific clinical 
characteristics. Of these, H3F3A K27M mutations have been included in the new WHO classification, with 
the designation of a new entity, the ‘diffuse midline glioma, H3 K27M mutant’. This raises the question 
as to which should be routinely assessed, which are optional but nice to have and which are without 
clinical relevance.  
1p/19q co-deletion.  
This is now part of standard diagnostics. 1p/19q loss was first identified in 1994 as the most 
characteristic genetic lesion in oligodendroglioma, associated with chemotherapy response in 1998, and 
subsequently assumed to be both prognostic for survival and predictive for benefit from the addition of 
PCV chemotherapy to radiotherapy.27-30 This combined 1p/19q loss is the result of a still poorly 
understood balanced translocation, in which both the whole p-arm of chromosome 1 and the whole q 
arm of chromosome are lost (‘classical’ 1p/19q co-deletion).31, 32 More recent data suggest that typical 
1p/19q loss is always associated with IDH mutations.6, 7, 26, 33 Since 1p and 19q loss occasionally occurs in 
other tumors, the finding of a 1p/19q deletion in the absence of an IDH mutation does not allow the 
diagnosis of an oligodendroglioma (figure 3). In childhood tumors with histopathological appearance of 
an oligodendroglioma 1p/19q  loss is usually absent, but 1p/19q co-deletion is occasionally identified in 
newly diagnosed oligodendroglial tumors in patients beyond 65 years of age.34  
 
IDH mutations 
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Assessing IDH mutations is now also part of standard diagnostics. Two types of IDH mutations are 
observed in glioma: in the IDH1 and in the IDH2 gene.  All mutations in IDH1 and IDH2 are somatic, 
missense, heterozygous, and affect codon 132 (IDH1) or codon 172 (IDH2). IDH mutations are mutually 
exclusive; 90% of all IDH mutations concern the IDH1 R132H mutation. Studies have shown that IDH 
mutations are early events in gliomagenesis, and remain present at the time of tumor progression.35, 36  
IDH mutated tumors occur in all grade II-IV diffuse glioma, but are absent in other primary brain tumors. 
If found in other histological subtypes this is likely to represent a histopathological misclassification. IDH 
mutations are common in adult grade II and III glioma, occurring in 70-80% of cases.36, 37 About 5-10% of 
glioblastoma show IDH mutations, in particular in patients below 50 years of age. In pediatric glioma IDH 
mutations are rare, but have been described in patients as young as 12 years of age.38 IDH mutated 
tumors have an improved outcome compared to non-IDH mutated tumors of similar histopathological 
grade. IDH mutations cause an altered enzyme substrate affinity, leading to increased levels of 2-
hydroxyglutarate and lower levels of α-ketoglutarate.39  One of the metabolic alterations that this 
induces is the development of a global methylation of CpG islands, including the MGMT gene promoter. 
This may explain some of the chemotherapy sensitivity of IDH mutated tumors; another explanation is 
that some of the chemotherapy resistance mechanisms are depending on α-ketoglutarate.40 It has been 
suggested IDH mutations can be used to identify patients that will benefit from adding chemotherapy to 
radiotherapy, other studies were however not confirming this and identified MGMT promoter 
methylation as the best predictive factor which is however usually present in IDHmt tumors.41, 42   
TP53 
TP53 mutations are predominantly observed exon 4-8, and occur in 95% of IDH mutated tumors without 
1p/19q co-deletion. They do however also occur in other glial tumors, including glioblastoma, in 1p/19q 
co-deleted tumors (although less frequently), in medulloblastoma and in pediatric glioma. Therefore 
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they lack diagnostic specificity and in glial tumors they are not associated with treatment outcome.  
There is currently no role for routine testing; if diagnosed they may support the diagnosis of several 
entities. 
Alpha-thalassemia syndrome gene (ATRX) 
Mutations in the ATRX gene occur in 70% of IDH mutated gliomas without 1p/19q co-deletion, the 
astrocytic type of glial tumor. They are mutually exclusive with TERT promoter (TERTp) mutations. There 
are no hot spot regions for ATRX mutations, and they can be sub-clonal with different ATRX mutations in 
different parts of the tumor and with different ATRX mutations at first diagnosis vs recurrent tumors. If 
present, they suggest an IDH mutated TP53 mutated astrocytoma. ATRX mutations also occur in H3 
mutated tumors. ATRX mutations can be assessed by immunohistochemistry and by sequencing. Loss of 
ATRX IHC staining in mutated tumors can be a rapid method to detect ATRX mutations, and it has been 
suggested it may obviate the need for 1p/19 testing.9 While some neuropathologists use ATRX IHC as a 
criterion to select which gliomas are to be tested for 1p/19q status, further experience is needed to test 
whether it can substitute for a 1p/19q test, but for now, the WHO 2016 classification explicitly does not 
accept positive staining for ATRX in IDH mutated tumors as an alternative to diagnose 1p/19q codeleted 
IDH mutated oligodendroglioma.  
 
Telomerase Reverse Transcriptase promoter ((TERTp) mutations 
Somatic hot spot mutations in the TERTp gene occur in IDHwt glioblastoma and in 1p/19q co-deleted IDH 
mutated oligodendroglioma.  As a consequence, simply assessing both TERTp and IDH mutational status 
already results in a very powerful prognostic glioma classification.7, 20, 43 In some tumors only TERTp 
mutations are found, without other typical glioma alterations; these patients tend to have a poor 
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outcome. TERTp mutations are mutually exclusive with ATRX mutations. Interestingly, patients with 
grade II and III IDHwt tumors but without a TERTp mutations appear to have a better prognosis 
compared to patients with TERTp mutations.  Typically, these studies have been lacking the assessment 
of chromosome 7 and 10q, which most likely would have identified a glioblastoma like chromosomal loss 
pattern in many of the IDHwt/TERTp mutated tumors.  More clinical outcome data on these tumors are 
urgently needed. Assessment of TERTp mutational status can be useful for IDHwt diffuse glioma, they are 
however not specific for glioma and for example occur also in medulloblastoma. 
The gain of 7 and loss of 10q genotype 
The combination of tri/polysomy of chromosome 7 and LOH of 10q is a characteristic combination found 
in many glioblastoma and probably represents an early event in these tumors.19, 44  Usually TERTp 
mutations are present, and in 40-50% of cases EGFR amplification usually with EGFR mutations, including 
EGFRvIII mutations in 20%.  Many IDHwt astrocytoma and anaplastic astrocytoma (especially in patients 
over 45 years of age) show this 7+/10q- pattern, and typically have a clinically aggressive course (figure 
1b).6, 45Testing for this combination in patients over 45-50 years of age with grade II of III IDHwt tumors 
may give positive indications for a poor prognosis. The WHO classification strongly suggests the diagnosis 
glioblastoma should be considered in 7+/10q- anaplastic  oligodendroglioma and anaplastic 
oligoastrocytoma, but these abnormalities do not  qualify for the diagnosis glioblastoma ion the current 
classification. The available clinical data support that despite these being histologically grade II or III 
tumors, that  these tumors should be treated as glioblastoma and many clinicians with routine access to 
diagnostics of 7 and 10q do so. 
Epidermal Growth Factor Receptor (EGFR) amplification and mutations 
EGFR amplification occurs in 40-50% of all glioblastoma, and is usually associated with EGFR mutations 
and trisomy/polysomy of chromosome 7.46 Most EGFR amplified tumors also show EGFR mutations 
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affecting the extracellular domain of the receptor, the most frequent being the EGFRvIII mutation. There 
is currently no drug that specifically or effectively exploits any of these mutations, although several trails 
on novel agents are ongoing. As a consequence, from both a therapeutic and a diagnostic aspect the 
routine assessing of EGFR amplification or EGFR mutations is currently not useful. The presence of EGFR 
amplification is indeed highly specific: if found it is diagnostic at the molecular level of a glioblastoma, 
but it lacks sensitivity: assays for EGFR amplification will be negative in 50% of the glioblastoma cases. 
Outcome of EGFR amplified or EGFRvIII mutated tumors is not different from other glioblastoma.47 
Currently, for glioblastoma diagnostics assessing both chromosome 7 and 10q or TERTp mutations is 
more informative than assessing EGFR amplification status.  
Phosphatase and Tensin Homolog (PTEN) 
PTEN mutations occur in 20-30% of glioblastoma, and are as a rule accompanied by LOH10q. When both 
are present this results in bi-allelic PTEN inactivation. They may also occur at low frequency in other 
gliomas with unclear clinical significance, and in other tumors (medulloblastoma). Thus, it has low 
diagnostic value and no therapeutic consequences. Routine assessment of PTEN mutations is clinically 
not indicated.  
BRAF-KIAA fusion genes and BRAF mutations in glial tumors 
Abnormalities in the BRAF gene  are characteristic of several  subgroup of gliomas. Pilocytic astrocytoma 
(PA) in the fossa posterior typically have a tandem duplication at 7q34 resulting in a transforming fusion 
gene between KIAA1549 and BRAF (BRAF duplication or BRAF-KIAA1549 fusion gene), but not the 
BRAFv600 mutation. BRAF-KIAA fusion genes are also frequent in non-NF1 optic nerve glioma (73%).48 
BRAF-KIAA1549 fusion are age specific, they are rare in PA patients over 40 years of age (7%).  BRAFv600 
mutations are mutually exclusive with the BRAF-KIAA549 fusion gene, these are observed in , 33% of the 
non-posterior fossa PA. They are also relatively common in  pleomorphic xantroastrocytoma (PXA;  43-
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66%), anaplastic PXA (65%) and ganglioglioma (18-43%) especially if located in the brain stem49-52; they 
are  rare in adult glioma (glioblastoma: 2%, adult low grade glioma: 0-3%).49  They are also frequent in 
the proposed novel (but rare) WHO entity of epitheloid glioblastoma, although their distinction from 
anaplastic PXA is unclear.53 A study on pediatric diencephalic low grade glioma reported frequent 
BRAFv600 mutated non-PA in this region, with imaging characteristics of vivid enhancement and 
multiloculated or multinodular appearance and/or infiltrative growth on T2 weighted images (figure 2).54  
A Canadian series observed BRAF fusion positivity in unilateral thalamic low grade tumors.55 Since BRAF 
mutated tumors may be treated with targeted agents aiming at the BRAFv600 mutations, either alone or 
in combination with a MERK pathway inhibitor, the finding of this abnormality may have therapeutic 
implications. Responses to these agents have been described, and this appears a very promising avenue 
of research.56 BRAF mutations and the BRAF-KIAA fusion have not been incorporated into the current 
diagnostic classification; the diagnosis of pilocytic astrocytoma remains a morphological definition. 
Routine testing must be considered in relevant cases.  Future research should focus on establishing to 
what extent these tumors share the same background, and to what extent other abnormalities in the 
RAS/RAF pathway may have a similar phenotypic effect. More rare genetic lesions in pilocytic 
astrocytoma include NF1,  KRAS and RAS mutations and FGFR1 and other BRAF fusions.57 
Histone H3F3A and HIST1H3B mutations 
The WHO 2016 has accepted the ’diffuse midline glioma, H3 K27M mutant’ as diagnostic entity, 
occurring predominantly in childhood and adolescent brain tumor patients. The mutation is part of a 
larger family of histone mutations with similar clinical presentation. Pediatric and young adult glioma 
frequently show mutations in genes encoding H3 variants, which through histone modification alter gene 
expression.58 Driver mutations occur in the H3F3A gene (positions K27 and G34) encoding histone H3.3 
genes, and in HIST1H3B histone H3.1 gene (K27 position). K27 mutated tumors typically arise in the 
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brainstem and midline structures such as thalamus and cerebellum, mostly in children and young adults. 
Thus, diffuse intrinsic pontine glioma (DIPG) frequently harbor K27M mutations in histone H3.3 genes as 
well as in H3.1 genes.59 Childhood and young adult supratentorial glioma may show mutations in histone 
H3.3, with K27M mutations occurring in midline tumors. In contrast, pG34R/V histone H3.3 mutations 
are restricted to pediatric and young adult HGGs of the cerebral cortex, and are almost invariably 
associated with ATRX and TP53 mutations.59, 60 K27 mutations are associated with a poor outcome; G34 
mutations appear to have better survival. Intrinsic pontine glioma harboring a K27M mutation in H3.3 
are less responsive to radiotherapy, with earlier relapses and more metastatic recurrences than those in 
H3.1.60 Although the K27M mutation was frequently observed in adult brainstem and thalamic gliomas, 
this mutation tended to be associated with a poorer prognosis in brainstem gliomas but not in thalamic 
gliomas.61  The presence of the H3F3A K27M mutation is associated with mutations in TP53.59, 62 An 
antibody against the K27M allele  may prove useful to facilitates detection of this mutation.63   The role 
of other mutations (e.g., ACVR1) in DIPG remain to be elucidated. Testing for H3F3A mutations is 
insightful in pediatric and young adult cases with midline tumors. 
 
Challenges: platforms and tests to be used 
The revised WHO 2016 criteria do not make recommendations how to assess molecular alterations, 
which is wise in view of the rapidly changing landscape of molecular diagnostics and testing platforms. 
With next generation sequencing techniques (NGS) becoming rapidly more affordable, NGS panels 
tailored for glioma diagnostics are increasingly being used for routine diagnostics including assessment 
of copy number alterations.64  Although there is clearly an advantage of the assessment of more than 
only IDH mutation and 1p/19q status, the routine use of screening for the 50 most frequent cancer 
genes or whole exome in glioma is without clinically proven benefit. Outside the identification of 
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molecular glioblastoma with WHO grade II or III histology, no proven therapeutic decisions can be taken 
based on these profiles, with BRAF mutant tumors as the most promising exception as they allow 
patients to be selected for clinical trials.56  Previous studies have shown the clinical usefulness of gene 
expression analysis and genome wide methylation analysis. In particular, the latter approach has been 
shown to be very informative, allowing the classification of tumors without knowledge of specific 
mutations. This classification system is based on the assumption that the methylation pattern of a tumor 
is the consequence of both the lineage of the cell the tumor arises from, and tumor specific DNA 
characteristics. For brain tumors, a relevant aspect here is that the analysis of methylation status 
simultaneously allows the assessment of MGMT status, which may well be the single most powerful 
determinant of benefit from alkylating agent chemotherapy.42, 45  
Assessment of molecular characteristics in every day practice and pitfalls 
Testing for IDH is part of routine diagnostics, but it seems reasonable to limit routine testing to an age 
range of 15 to 55 - 60 years, for example, and test beyond that only on clinical indications (e.g. in all 
adult grade II and III glioma, in the presence of oligodendroglial features, and in case of a hemispheric 
astrocytoma in a 13 year old). For the R132H mutation a very reliable immunohistochemistry (IHC) assay 
is available, but this represents only 90% of all IDH mutations.  As a consequence, IHC has at best a 90% 
sensitivity, implying that in case of IHC negativity this must be followed by sequencing for both IDH1 and 
IDH2 mutations (figure 4). IHC can be used as a first screen, but not as a tool to rule out IDH mutations. 
Testing for 1p/19q status and IDH mutations should be performed  in all patients presenting with 
possible oligodendroglial tumors. Testing for 1p/9q status should use an assay that allows assessment of 
loss of the entire 1p and 19q arm. Fluorescence in situ hybridization (FISH) for 1p using a probe for 
1p36.6 region is less specific as it may suggest loss in tumors with partial 1p deletion only, limited to the 
tip of chromosome 1p.65, 66 This part can be lost without loss of the rest of chromosome 1p, which in 
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combination with 19q loss has been observed in glioblastoma. If copy number alterations (CNA) are 
considered to be relevant this should be assessed with other techniques. Both 1p/19q co-deletions and 
IDH mutations are early events in gliomagenesis, and  their presence or absence are unlikely to change 
over time.67, 68 Therefore, retesting of 1p/19q and IDH status at the time of a re-resection in tumors with 
already known status is of limited use, unless a significant clinical change occurred indicating a second 
tumor.  Incorporation of assessment of TERTp mutations into routine diagnostics of gliomas has been 
suggested.20 In the absence of 1p/19q loss,  diffuse gliomas with TERTp mutations tend to have a poor 
outcome reminiscent of glioblastoma.7, 43 Although some studies on targeted mutation assessment have 
shown that in some tumors only TERTp mutations were observed, this deserves further clinical study 
since in most of these series tumors were not tested for CNA of 7 and 10q.  
Reporting 
Centers must develop automated workflows that incorporate molecular testing in their routine 
procedures, including the incorporation of the molecular diagnostics in the final pathology result. It is 
important for the reporting of the diagnosis to be standardized and made available for capture in the 
national cancer registry databases, so the incidence of the specific entities based on molecular features 
can be reported. Since the turnaround time for histopathology is shorter than for molecular diagnostics, 
ensuring accurate and timely feedback on molecular findings in patients in whom a histopathological 
diagnosis has already been established is important. It is recommended to routinely include (MR) 
imaging characteristics in the final diagnostic considerations: MRI images should be consistent with the 
pathological diagnosis and if not this should give rise to additional scrutiny.  The interpretation of 
molecular findings depends on the context: if the tumor is unlikely to be a diffuse glioma the molecular 
findings may not contribute except when an diagnostic mutation is found with supportive MR and clinical 
findings. 
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Clinical studies 
With the new classification, the clinical data from past trials without molecular analysis have become 
outdated. Since the first results of the trials on anaplastic oligodendroglioma, follow-up trials in the 
newly diagnosed setting (CODEL, CATNON) but also in recurrent disease (TAVAREC) enrolled patients 
based on their 1p/19q status because of the difference in prognosis, and many prospective trials 
reported retrospectively on the molecular status (table 3).  New studies should now distinguish between 
IDH mutant tumors, IDH mutant and 1p/19q co-deleted, and IDH wild type diffuse gliomas. This 
complicates matters. As an example, the presence of IDH mutations also identifies a more favorable 
subgroup of glioblastoma which may also hold true at the time of recurrence.69 This questions whether 
these tumors should be enrolled in trials on recurrent glioblastomas and whether it should be routinely 
tested for. On the other hand, the still modest survival of IDH mutated glioblastoma also argues against 
enrolling these tumors in trials aiming at IDH mutated diffuse grade II and III glioma although the limited 
difference in outcome between grade II and III IDH mutated tumors provides a rational for combining 
these grades.15 Today’s changes emphasize that all trials should collect tissue samples as part of the 
study design. Analysis of existing datasets may help to improve our understanding of the outcome of 
these subsets of patients.  
Quality control 
The interobserver variation in the histopathological classification of glioma is well known,  but early 
experiences with inter-laboratory tests on diagnostic molecular assays on the same set of tumors 
revealed that differences between laboratories may exist as well.70, 71 Proper quality control is critical 
now that diagnostics and clinical decisions are based on molecular testing. Laboratories need to certify 
and validate their testing procedures with appropriate controls. This is not exciting work and requires 
significant efforts, but is absolutely essential for reliable diagnostics.  
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Conclusion. 
The new WHO 2016 classification for brain tumors brings molecular diagnostics to the center of glioma 
classification. This revised classification will improve treatment selection of brain tumor patients and 
clinical trial design. This will not be the last revision of this classification as new molecular insights into 
brain tumors will further refine the classification of brain tumors. Further refinements already seem 
indicated, e.g., in the IDH wild type categories of grade II and III glioma as these represent in many cases 
–especially in patients over 50 years of age- glioblastoma -like lesions with 7+/10q LOH. Further analysis 
of TERTp mutational status in non-glioblastoma 1p/19q intact tumors will be needed to better 
understand the prognostic role of that mutation in diffuse glioma. More responsiveness to the rapidly 
changing and multidisciplinary field of neuro-oncology will be crucial to maintain a well-accepted WHO 
classification of brain tumors.  For this, a more transparent and multidisciplinary process of change of 
these pivotal criteria will be needed. 
 
  
  N-O-D-16-00602R1 
21 
 
REFERENCES 
 
 1.  Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of 
Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-
820. 
 2.  van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on 
glioma: a clinician's perspective. Acta Neuropathol. 2010;120(3):297-304. 
 3.  Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor 
classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 
2014;128(4):551-559. 
 4.  Wick W, Hartmann C, Engel C, et al. NOA-04 Randomized Phase III Trial of Sequential 
Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or 
Temozolomide. J Clin Oncol. 2009;27):5874-5880. 
 5.  Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of oligodendroglial 
neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J 
Clin Oncol. 2006;24(34):5419-5426. 
 6.  Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic 
oligodendroglioma using next generation sequencing . A report of the prospective 
randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol. 2016;18):388-
400. 
  N-O-D-16-00602R1 
22 
 
 7.  Labussiere M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic 
associations and clinico-pathological correlations. Br J Cancer. 2014;111(10):2024-2032. 
 8.  Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse 
Lower-Grade Gliomas. N Engl J Med. 2015;372):2481-2498. 
 9.  Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with 
subsequent copy number analysis and IDH sequencing as a basis for an "integrated" 
diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta 
Neuropathol. 2015;129(1):133-146. 
 10.  Louis DN, Ohgaki H, Wiestler OD, et al.: WHO classification of tumours of the central nervous 
sytem (ed revised 4th edition), Lyon, 2016 
 11.  Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central 
Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 
2015;17 Suppl 4):iv1-iv62. 
 12.  Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of 
oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56):1098-1104. 
 13.  Herrlinger U, Jones DT, Glas M, et al. Gliomatosis cerebri: no evidence for a separate brain tumor 
entity. Acta Neuropathol. 2016;131(2):309-319. 
 14.  Taal W, van der Rijt CC, Dinjens WN, et al. Treatment of large low-grade oligodendroglial tumors 
with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a 
retrospective cohort study with growth kinetics. J Neurooncol. 2015;121(2):365-372. 
  N-O-D-16-00602R1 
23 
 
 15.  Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have 
similar age at presentation and little difference in survival: a grading problem for WHO. 
Acta Neuropathol. 2015;129(6):867-873. 
 16.  Draaisma K, Wijnenga MM, Weenink B, et al. PI3 kinase mutations and mutational load as poor 
prognostic markers in diffuse glioma patients. Acta Neuropathol Commun. 2015;3):88. 
 17.  Houillier C, Mokhtari K, Carpentier C, et al. Chromosome 9p and 10q losses predict unfavorable 
outcome in low-grade gliomas. Neuro Oncol. 2010;12(1):2-6. 
 18.  Alentorn A, Dehais C, Ducray F, et al. Allelic loss of 9p21.3 is a prognostic factor in 1p/19q 
codeleted anaplastic gliomas. Neurology. 2015;85(15):1325-1331. 
 19.  Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III 
gliomas using genome- and transcriptome-wide profiling improves stratification of 
prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679-693. 
 20.  Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT 
Promoter Mutations in Tumors. N Engl J Med. 2015;372(26):2499-2508. 
 21.  Pajtler KW, Witt H, Sill M, et al. Molecular Classification of Ependymal Tumors across All CNS 
Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015;27(5):728-
743. 
 22.  Ramaswamy V, Hielscher T, Mack SC, et al. Therapeutic Impact of Cytoreductive Surgery and 
Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective 
Multicohort Analysis. J Clin Oncol. 2016. 
  N-O-D-16-00602R1 
24 
 
 23.  Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human 
oligodendroglioma. Science. 2011;333(6048):1453-1455. 
 24.  Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, 
oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012;123(6):853-860. 
 25.  Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the 
classification of malignant gliomas. Oncotarget. 2012;3(7):709-722. 
 26.  Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss 
distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7-16. 
 27.  Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analsysis of oligodendroglial tumors 
shows preferential allelic deletions on 19q and 1p. Amer J Pathol. 1994;145):1175-1190. 
 28.  Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response 
and survival in patients with anaplastic oligodendrogliomas. J Natl Canc Inst. 
1998;90):1473-1479. 
 29.  Cairncross JG: Chemotherapy plus radiotherapy versus radiotherapy alone for patients with 
anaplastic olgidendroglioma: long term results of RTOG 9402. Proc Am Soc Clin Oncol 
abstract #2008b, 2012 (abstr) 
 30.  van den Bent MJ: Long term follow-up results of EORTC 26951: a randomized phase III study on 
adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors. Proc Am Soc Clin 
Oncol:abstract #2, 2012 (abstr) 
  N-O-D-16-00602R1 
25 
 
 31.  Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p 
and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 
2006;66(20):9852-9861. 
 32.  Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five 
oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp 
Neurol. 2006;65(10):988-994. 
 33.  Wang XW, Ciccarino P, Rossetto M, et al. IDH mutations: genotype-phenotype correlation and 
prognostic impact. Biomed Res Int. 2014;2014):540236. 
 34.  Rodriguez FJ, Tihan T, Lin D, et al. Clinicopathologic features of pediatric oligodendrogliomas: a 
series of 50 patients. Am J Surg Pathol. 2014;38(8):1058-1070. 
 35.  Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade 
astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J 
Neurooncol. 2012;108(3):403-410. 
 36.  Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta 
Neuropathol. 2008;116(6):597-602. 
 37.  Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to 
astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. 
Acta Neuropathol. 2009;118(4):469-474. 
 38.  Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pediatric glioblastoma reveals a 
subset of biologically favorable tumors with associated molecular prognostic markers. Acta 
Neuropathol. 2015;129(5):669-678. 
  N-O-D-16-00602R1 
26 
 
 39.  Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block 
to cell differentiation. Nature. 2012. 
 40.  Wang P, Wu J, Ma S, et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair 
Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015;13(11):2353-
2361. 
 41.  Cairncross JG, Wang M, Jenkins RB, et al. Benefit From Procarbazine, Lomustine, and Vincristine in 
Oligodendroglial Tumors Is Associated With Mutation of IDH. J Clin Oncol. 2014;32(8):783-
790. 
 42.  van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive 
marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A 
report from EORTC study 26951. Clin Cancer Res. 2013;19(19):5513-5522. 
 43.  Yang P, Cai J, Yan W, et al. Classification based on mutations of TERT promoter and IDH 
characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016;18(8):1099-1108. 
 44.  Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a 
common proneural-like precursor glioma. Cancer Cell. 2014;26(2):288-300. 
 45.  Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify 
three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 
2014;128(4):561-571. 
 46.  Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 
2013;155(2):462-477. 
  N-O-D-16-00602R1 
27 
 
 47.  Weller M, Kaulich K, Hentschel B, et al. Assessment and prognostic significance of the epidermal 
growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and 
adjuvant temozolomide radiochemotherapy. Int J Cancer. 2014;134(10):2437-2447. 
 48.  Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, et al. BRAF duplications and MAPK pathway activation 
are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol. 
2012;71(9):789-794. 
 49.  Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system 
tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, 
ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 
2011;121(3):397-405. 
 50.  Gierke M, Sperveslage J, Schwab D, et al. Analysis of IDH1-R132 mutation, BRAF V600 mutation 
and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports 
pediatric tumor classification. J Cancer Res Clin Oncol. 2016;142(1):89-100. 
 51.  Gupta K, Orisme W, Harreld JH, et al. Posterior fossa and spinal gangliogliomas form two distinct 
clinicopathologic and molecular subgroups. Acta Neuropathol Commun. 2014;2):18. 
 52.  Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial 
tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with 
morphology. Acta Neuropathol. 2016. 
 53.  Alexandrescu S, Korshunov A, Lai SH, et al. Epithelioid Glioblastomas and Anaplastic Epithelioid 
Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins? Brain Pathol. 
2016;26(2):215-223. 
  N-O-D-16-00602R1 
28 
 
 54.  Ho CY, Mobley BC, Gordish-Dressman H, et al. A clinicopathologic study of diencephalic pediatric 
low-grade gliomas with BRAF V600 mutation. Acta Neuropathol. 2015;130(4):575-585. 
 55.  Steinbok P, Gopalakrishnan CV, Hengel AR, et al. Pediatric thalamic tumors in the MRI era: a 
Canadian perspective. Childs Nerv Syst. 2016;32(2):269-280. 
 56.  Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF 
V600 Mutations. N Engl J Med. 2015;373(8):726-736. 
 57.  Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and 
markers. Acta Neuropathol. 2015;129(6):775-788. 
 58.  Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic 
pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251-253. 
 59.  Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and 
pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444-450. 
 60.  Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two 
subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. 
Acta Neuropathol. 2015;130(6):815-827. 
 61.  Feng J, Hao S, Pan C, et al. The H3.3 K27M mutation results in a poorer prognosis in brainstem 
gliomas than thalamic gliomas in adults. Hum Pathol. 2015;46(11):1626-1632. 
 62.  Aihara K, Mukasa A, Gotoh K, et al. H3F3A K27M mutations in thalamic gliomas from young adult 
patients. Neuro Oncol. 2014;16(1):140-146. 
  N-O-D-16-00602R1 
29 
 
 63.  Venneti S, Santi M, Felicella MM, et al. A sensitive and specific histopathologic prognostic marker 
for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128(5):743-753. 
 64.  Dubbink HJ, Atmodimedjo PN, van MR, et al. Diagnostic Detection of Allelic Losses and Imbalances 
by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. J Mol Diagn. 
2016;18(5):775-786. 
 65.  Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance 
in gliomas. Ann Neurol. 2005;58(3):483-487. 
 66.  Idbaih A, Kouwenhoven M, Jeuken J, et al. Chromosome 1p loss evaluation in anaplastic 
oligodendrogliomas. Neuropathology. 2008. 
 67.  Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of 
astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153. 
 68.  Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analysis in 
recurrent oligodendroglioma. J Neuropathol Exp Neurol. 2004;63):314-322. 
 69.  Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a 
combination of bevacizumab plus lomustine in patients with recurrent glioblastoma 
(BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953. 
 70.  van den Bent MJ, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation 
detection. J Neurooncol. 2013;112.):173-178. 
 71.  Preusser M, Wohrer A, Stary S, et al. Value and limitations of immunohistochemistry and gene 
sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. 
J Neuropathol Exp Neurol. 2011;70(8):715-723. 
  N-O-D-16-00602R1 
30 
 
72. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade 
Glioma. N Engl J Med. 2016;374(14):1344-1355. 
73. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant Procarbazine, Lomustine, and Vincristine 
Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up 
of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013;31):344-350. 
74. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic 
oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343. 
75. Chang SM, Zhang P, Cairncross JG, et al.: Results of NRG oncology/RTOG 9813: A phase III 
randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and 
nitrosourea (NU) therapy for anaplastic astrocytoma (AA). J Clin Oncol 33:#2002, 2015 
(abstr) 
76. Wick W, Roth P, Hartmann C, et al. Long-term analysis of the NOA-04 randomized phase III trial of 
sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro 
Oncol. 2016. 
 
 
 
 
  
  N-O-D-16-00602R1 
31 
 
Figures 
Figure 1 Glioblastoma diagnostics anno 2016. 1a. T1 weighted MR images of a 40 year old male with a 
short history headache and difficulty walking . At histopathology a glioblastoma was diagnosed, targeted 
sequencing showed an IDH2 mutation, combined 1p/19q loss and deletion of chromosome 9 consistent 
with the diagnosis of an anaplastic oligodendroglioma; 1b. T1 weighted contrast enhanced MR image of 
a 50 year old female who developed over months progressive memory and behavioral complaints.  No 
contrast enhancement was present, at biopsy histopathology showed a grade II  astrocytoma, Next 
Generation Sequencing failed to show an IDH mutation but instead documented gain of chromosome 7, 
loss of 10q, and mutations in the  EGFR  and PTEN gene consistent with a glioblastoma. 
Figure 2. T2 weighted images of a 25 year old male who underwent two biopsies for a mesencephalic 
lesion, on both occasions histopathological examination failed to show clear evidence of tumor. On 
mutational analysis, a BRAF mutation was found (c.1795_1797dupACA;p.T599dup) 
 
Figure 3. T1 contrast enhanced MR images of a ring right frontal enhancing lesion tumor 
histopathologically classified as glioblastoma,  at molecular examination 1p/19q co-deletion was found 
but with neither an IDH nor a TERTp mutation, 
Figure 4. T2 weighted MR images of a right frontal low grade astrocytoma in a 20 year old, diagnosed as 
IDH wt because of negative immunohistochemistry. After referral to a tertiary care center sequencing 
demonstrated an IDH  c.394C>T; p.R132C  mutation in combination with a TP53 and an ATRX mutation. 
 
Table 1. The WHO 2016 classification for astrocytoma, oligodendroglioma and ependymoma and ICD10 
code.  
WHO 2016 classification of astrocytoma, oligodendroglioma and ependymoma 
Diffuse astrocytoma and oligodendroglial tumors ICD code 
Diffuse astrocytoma, IDH mutant 9400/1 
Gemistocytic astrocytoma, IDH mutant 9411/3 
Diffuse astrocytoma, IDH wildtype 9400/3 
Diffuse astrocytoma, NOS 9400/3 
  
Anaplastic astrocytoma, IDH mutant 9401/3 
Anaplastic astrocytoma, IDH wild type 9401/3 
Anaplastic astrocytoma. NOS 9401/3 
  
Glioblastoma, IDH wild type 9440/3 
 Giant cell glioblastoma 9441/3 
 Gliosarcoma 9442/3 
 Epitheloid glioblastoma 9440/3 
Glioblastoma, IDH mutant 9445/3 
Glioblastoma, NOS 9440/3 
  
Diffuse midline glioma, H3 K27M-mutant 9385/3 
  
Oligodendroglioma, IDH mutant and 1p/19q co-deleted 9450/3 
Oligodendroglioma, NOS 9450/3 
  
Anaplastic oligodendroglioma, IDH mutant and 1p/19q co-
deleted 
9451/3 
Anaplastic oligodendroglioma, NOS 9451/3 
  
Oligoastrocytoma NOS 9382/3 
Anaplastic oligoastrocytoma 9382/3 
  
Other astrocytic tumors 
Pilocytic astroctyoma 9421/1 
Pilomyxoid astrocytoma 9425/3 
Subependymal  giant cell astrocytoma 9424/3 
Anaplastic pleomorphic xanthoastrocytoma 9424/3 
  
Ependymal tumors 
Subependymoma 9383/1 
Myxopapillary ependymoma 9394/1 
Ependymoma 9391/3 
 Papillary ependymoma 9393/3 
 Clear cell ependymoma 9391/3 
 Tancytic ependymoma 9391/3 
Ependymoma, RELA fusion positive 9396/3 
Anaplastic ependymoma 9392/3 
Table 1
 
  
Table 2. Survival in various molecular subtypes as reported in randomized controlled clinical studies with molecular analysis and mature overall 
survival results.  
 
 
 
 
 
 
study histology Molecular subtype treatment n Median OS Median PFS 
RTOG 980272 Low grade glioma 
IDH mutated (all) 
IDHwt 
RT/PCV or RT 
RT/PCV or RT 
71 
42 
13.1 yrs 
5.1 years 
 
EORTC 269516, 73 
Anaplastic 
oligodendroglioma 
1p/19q codeleted 
IDHmt 1p/19q intact 
7+/10q-/TERTpmt 
RT/PCV 
RT/PCV 
RT or RT/PCV 
43 
23 
55 
NR (>14 yrs) 
8.3 yrs 
1.13 yrs 
147 
4.2 yrs 
NS 
RTOG 940274 
Anaplastic 
oligodendroglioma 
1p/19q IDHmt (all) RT/PCV 
 
59 14.7 yrs 8.4 yrs 
RTOG 980475 
Anaplastic 
astrocytoma 
IDH mt (IHC) 
IDHwt 
RT/chemo 49 
54 
7.9 yrs 
2.8 yrs 
 
NOA476 Grade III 
1p/19q codeleted 
IDHmt 1p/19q intact 
IDHwt 
RT or chemo 66 
83 
58 
NR 
7.0-7.3 yrs 
3.1 – 4.7 yrs 
 
Table 2
Figure 1a, b Click here to download Figure figure 1a_b_glioblastoma_1p19q idh.tif 
Figure 2 Click here to download Figure fig 2_T2_BRAFmt.tif 
Figure 3 Click here to download Figure fig 3_1p19q deleted no IDHmt.tif 
Figure 4 Click here to download Figure fig 4_T2 IDH IHC neg seq IDH
mut pos.tif
